UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________________________

FORM 10-Q

______________________________



x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED ~~JANUARY~~OCTOBER 27, 2018.



¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File No. 0-20572

_____________________________

PATTERSON COMPANIES, INC.

(Exact Name of Registrant as Specified in Its Charter)



Minnesota	41-0886515
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification Number)

1031 Mendota Heights Road St. Paul, Minnesota	55120
(Address of Principal Executive Offices)	(Zip Code)

(651) 686-1600

(Registrant’s Telephone Number, Including Area Code)

______________________________

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically ~~and posted on its corporate Web site, if any,~~ every Interactive Data File required to be submitted ~~and posted~~ pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit ~~and post~~ such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):



Large accelerated filer	x	Accelerated filer	¨	Non-accelerated filer	¨

Smaller reporting company	¨	Emerging growth company	¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

As of ~~March 1,~~November 29, 2018, there were ~~94,634,000~~94,954,000 shares of Common Stock of the registrant issued and outstanding.

PATTERSON COMPANIES, INC.

INDEX



	Page
PART I - FINANCIAL INFORMATION

Item 1- Financial Statements	3

Condensed Consolidated Balance Sheets ~~as of January 27, 2018 and April 29, 2017~~	3

Condensed Consolidated Statements of Income and Other Comprehensive Income ~~for the Three and Nine Months Ended January 27, 2018 and January 28, 2017~~	4

Condensed Consolidated Statements of ~~Cash Flows for the Nine Months Ended January 27, 2018 and January 28, 2017~~Changes in Stockholders' Equity	5

Condensed Consolidated Statements of Cash Flows	6

Notes to Condensed Consolidated Financial Statements	67

Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations	1419

Item 3 - Quantitative and Qualitative Disclosures about Market Risk	2025

Item 4 - Controls and Procedures	2025

PART II - OTHER INFORMATION

Item 1 - Legal Proceedings	2126

Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds	2229

Item 6 - Exhibits	2330

Signatures	2431

PART I—FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

PATTERSON COMPANIES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In ~~thousands)~~thousands, except per share amounts)

(Unaudited)


	January 27, 2018			April 29, 2017
	(Unaudited)						October 27, 2018			April 28, 2018
ASSETS
Current assets:
Cash and cash equivalents	$	118,005		$	94,959		$	165,515		$	62,984
Receivables, net of allowance for doubtful accounts	863,455			884,803			571,232			826,877
Inventory	882,018			711,903			792,533			779,834
Prepaid expenses and other current assets	116,310			111,928			176,019			103,029
Total current assets	1,979,788			1,803,593			1,705,299			1,772,724
Property and equipment, net	287,439			298,452			289,602			290,590
Long-term receivables, net	121,675			101,529			86,513			135,175
Goodwill	816,808			813,547			814,348			815,977
Identifiable intangibles, net	399,566			425,436			368,185			389,424
Other	69,082			65,356			80,307			67,774
Total assets	$	3,674,358		$	3,507,913		$	3,344,254		$	3,471,664
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	654,792		$	616,859		$	662,731		$	610,368
Accrued payroll expense	53,156			56,881			61,602			69,099
Other accrued liabilities	138,384			156,437			164,301			136,316
Current maturities of long-term debt	74,754			14,754			80,286			76,598
Borrowings on revolving credit	179,000			59,000			—			16,000
Total current liabilities	1,100,086			903,931			968,920			908,381
Long-term debt	931,419			998,272			738,341			922,030
Other non-current liabilities	179,863			211,277			181,305			179,463
Total liabilities	2,211,368			2,113,480			1,888,566			2,009,874
Stockholders’ equity:
Common stock	947			966
Common stock, $.01 par value: 600,000 shares authorized; 94,950 and 94,756 shares issued and outstanding							950			948
Additional paid-in capital	95,866			72,973			116,112			103,776
Accumulated other comprehensive loss	(66,763		)	(92,669		)	(86,733		)	(74,974		)
Retained earnings	1,501,011			1,481,234			1,473,357			1,497,766
Unearned ESOP shares	(68,071		)	(68,071		)	(51,722		)	(65,726		)
Total Patterson Companies, Inc. stockholders' equity							1,451,964			1,461,790
Noncontrolling interests							3,724			—
Total stockholders’ equity	1,462,990			1,394,433			1,455,688			1,461,790
Total liabilities and stockholders’ equity	$	3,674,358		$	3,507,913		$	3,344,254		$	3,471,664

See accompanying notes

PATTERSON COMPANIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

AND OTHER COMPREHENSIVE INCOME

(In thousands, except per share amounts)

(Unaudited)


	Three Months Ended						Nine Months Ended						Three Months Ended						Six Months Ended
	January 27, 2018			January 28, 2017			January 27, 2018			January 28, 2017			October 27, 2018			October 28, 2017			October 27, 2018			October 28, 2017
Net sales	$	1,375,222		$	1,397,418		$	4,065,074		$	4,148,095		$	1,404,752		$	1,385,737		$	2,741,072		$	2,689,852
Cost of sales	1,080,486			1,067,657			3,155,547			3,182,196			1,109,676			1,069,994			2,162,333			2,075,061
Gross profit	294,736			329,761			909,527			965,899			295,076			315,743			578,739			614,791
Operating expenses	244,690			283,207			730,889			774,126			253,860			243,984			533,009			486,199
Operating income from continuing operations	50,046			46,554			178,638			191,773
Operating income													41,216			71,759			45,730			128,592
Other income (expense):
Other income, net	2,096			994			4,768			4,980			5,941			1,160			7,194			2,672
Interest expense	(11,783		)	(11,400		)	(34,454		)	(31,659		)	(9,456		)	(11,468		)	(20,677		)	(22,671		)
Income from continuing operations before taxes	40,359			36,148			148,952			165,094
Income tax expense (benefit)	(68,596		)	8,379			(31,094		)	52,663
Net income from continuing operations	108,955			27,769			180,046			112,431
Net loss from discontinued operations	—			(3,229		)	—			(3,229		)
Income before taxes													37,701			61,451			32,247			108,593
Income tax expense													9,055			21,207			8,110			37,502
Net income	$	108,955		$	24,540		$	180,046		$	109,202		28,646			40,244			24,137			71,091
Basic earnings (loss) per share:
Continuing operations	$	1.18		$	0.29		$	1.94		$	1.18
Discontinued operations	—			(0.03		)	—			(0.03		)
Net basic earnings per share	$	1.18		$	0.26		$	1.94		$	1.15
Diluted earnings (loss) per share:
Continuing operations	$	1.18		$	0.29		$	1.93		$	1.17
Discontinued operations	—			(0.03		)	—			(0.03		)
Net diluted earnings per share	$	1.18		$	0.26		$	1.93		$	1.14
Net loss attributable to noncontrolling interests													(223		)	—			(276		)	—
Net income attributable to Patterson Companies, Inc.													$	28,869		$	40,244		$	24,413		$	71,091
Earnings per share attributable to Patterson Companies, Inc.:
Basic													$	0.31		$	0.43		$	0.26		$	0.76
Diluted													$	0.31		$	0.43		$	0.26		$	0.76
Weighted average shares:
Basic	91,949			94,737			92,674			95,252			92,683			92,722			92,606			93,037
Diluted	92,609			95,359			93,323			95,915			93,289			93,351			93,144			93,683
Dividends declared per common share	$	0.26		$	0.24		$	0.78		$	0.72		$	0.26		$	0.26		$	0.52		$	0.52
Comprehensive income
Comprehensive income:
Net income	$	108,955		$	24,540		$	180,046		$	109,202		$	28,646		$	40,244		$	24,137		$	71,091
Foreign currency translation gain (loss)	16,475			6,082			24,594			(28,176		)	(3,540		)	(3,965		)	(12,860		)	8,119
Cash flow hedges, net of tax	437			437			1,312			1,307			552			438			1,101			875
Comprehensive income	$	125,867		$	31,059		$	205,952		$	82,333		$	25,658		$	36,717		$	12,378		$	80,085

See accompanying notes

PATTERSON COMPANIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(In thousands)

(Unaudited)



	Common Stock					Additional Paid-in Capital		Accumulated Other Comprehensive Income (Loss)			Retained Earnings			Unearned ESOP Shares			Non-controlling Interests			Total
	Shares		Amount			Additional Paid-in Capital		Accumulated Other Comprehensive Income (Loss)			Retained Earnings			Unearned ESOP Shares			Non-controlling Interests			Total
Balance at April 29, 2017	96,534		$	966		$	72,973	$	(92,669	)	$	1,481,234		$	(68,071	)	$	—		$	1,394,433
Foreign currency translation	—		—			—		15,824			—			—			—			15,824
Cash flow hedges	—		—			—		1,871			—			—			—			1,871
Net income (loss)	—		—			—		—			200,974			—			—			200,974
Dividends declared	—		—			—		—			(96,964		)	—			—			(96,964		)
Common stock issued and related tax benefits	369		4			12,403		—			—			—			—			12,407
Repurchases of common stock	(2,147	)	(22		)	—		—			(87,478		)	—			—			(87,500		)
Stock based compensation	—		—			18,400		—			—			—			—			18,400
ESOP activity	—		—			—		—			—			2,345			—			2,345
Balance at April 28, 2018	94,756		948			103,776		(74,974		)	1,497,766			(65,726		)	—			1,461,790
Foreign currency translation	—		—			—		(12,860		)	—			—			—			(12,860		)
Cash flow hedges	—		—			—		1,101			—			—			—			1,101
Net income (loss)	—		—			—		—			24,413			—			(276		)	24,137
Dividends declared	—		—			—		—			(48,822		)	—			—			(48,822		)
Common stock issued and related tax benefits	194		2			2,710		—			—			—			—			2,712
Stock based compensation	—		—			9,626		—			—			—			—			9,626
ESOP activity	—		—			—		—			—			14,004			—			14,004
Increase from business combination	—		—			—		—			—			—			4,000			4,000
Balance at October 27, 2018	94,950		$	950		$	116,112	$	(86,733	)	$	1,473,357		$	(51,722	)	$	3,724		$	1,455,688

PATTERSON COMPANIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)


	Nine Months Ended						Six Months Ended
	January 27, 2018			January 28, 2017			October 27, 2018			October 28, 2017
Operating activities:
Net income	$	180,046		$	109,202		$	24,137		$	71,091
Net loss from discontinued operations	—			(3,229		)
Net income from continuing operations	180,046			112,431
Adjustments to reconcile net income from continuing operations to net cash provided by (used in) operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	33,672			29,037			22,145			22,458
Amortization	29,115			34,019			19,781			19,375
Intangible asset impairment	—			36,312
Bad debt expense	4,471			1,013			3,533			3,716
Non-cash employee compensation	22,999			17,254			13,926			16,635
Deferred income taxes	(38,299		)	(7,220		)
Deferred consideration in securitized receivables							(165,567		)	(24,581		)
Change in assets and liabilities, net of acquired	(191,991		)	(232,257		)	282,259			(31,586		)
Net cash provided by (used in) operating activities- continuing operations	40,013			(9,411		)
Net cash used in operating activities- discontinued operations	—			(3,229		)
Net cash provided by (used in) operating activities	40,013			(12,640		)
Net cash provided by operating activities							200,214			77,108
Investing activities:
Additions to property and equipment	(28,239		)	(37,457		)	(22,094		)	(16,431		)
Collection of deferred purchase price receivables	37,068			38,964			165,567			24,581
Other investing activities	10,600			(3,095		)	2,875			11,626
Net cash provided by (used in) investing activities- continuing operations	19,429			(1,588		)
Net cash provided by investing activities- discontinued operations	—			—
Net cash provided by (used in) investing activities	19,429			(1,588		)
Net cash provided by investing activities							146,348			19,776
Financing activities:
Dividends paid	(74,641		)	(70,947		)	(49,980		)	(49,969		)
Repurchases of common stock	(87,500		)	(84,651		)	—			(71,254		)
Debt amendment costs	—			(1,266		)
Retirement of long-term debt	(7,377		)	(22,550		)	(180,321		)	(7,377		)
Draw on revolver	120,000			178,000
Draw on (payment on) revolving credit							(16,000		)	33,000
Other financing activities	7,546			5,495			3,592			3,561
Net cash provided by (used in) financing activities	(41,972		)	4,081
Net cash used in financing activities							(242,709		)	(92,039		)
Effect of exchange rate changes on cash	5,576			(5,567		)	(1,322		)	1,652
Net change in cash and cash equivalents	23,046			(15,714		)	102,531			6,497
Cash and cash equivalents at beginning of period	94,959			137,453			62,984			94,959
Cash and cash equivalents at end of period	$	118,005		$	121,739		$	165,515		$	101,456

See accompanying notes

PATTERSON COMPANIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars, except per share amounts, and shares in thousands)

(Unaudited)

Note 1. General

Basis of Presentation

In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to present fairly the financial position of Patterson Companies, Inc. (referred to herein as "Patterson" or in the first person notations "we," "our," and "us") as of ~~January~~October 27, 2018, and our results of operations and cash flows for the periods ended ~~January~~October 27, 2018 and ~~January~~October 28, 2017. Such adjustments are of a normal recurring nature. The results of operations for the ~~periods~~three and six months ended ~~January~~October 27, 2018 ~~and January 28, 2017~~ are not necessarily indicative of the results to be expected for any other interim period or for the ~~full year.~~year ending April 27, 2019. These financial statements should be read in conjunction with the financial statements included in our ~~2017~~2018 Annual Report on Form 10-K filed on June ~~28, 2017.~~27, 2018.

The unaudited condensed consolidated financial statements include the assets and liabilities of PDC Funding Company, LLC ("PDC Funding") ~~and~~, PDC Funding Company II, LLC ("PDC Funding II") and PDC Funding Company III, LLC ("PDC Funding III"), which are our wholly owned subsidiaries and separate legal entities formed under Minnesota law. PDC Funding and PDC Funding II are fully consolidated special purpose entities established to sell customer installment sale contracts to outside financial institutions in the normal course of their business. PDC Funding III is a fully consolidated special purpose entity established to sell certain receivables to unaffiliated financial institutions. The assets of PDC Funding, PDC Funding II and PDC Funding IIIII would be available first and foremost to satisfy the claims of its creditors. There are no known creditors of PDC Funding, PDC Funding II or PDC Funding ~~II.~~III. The unaudited condensed consolidated financial statements also include the assets and liabilities of Technology Partner Innovations, LLC, which is further described in Note 7.

Fiscal Year End

We operate with a 52-53 week accounting convention with our fiscal year ending on the last Saturday in April. The ~~third~~second quarter of fiscal ~~2018~~2019 and ~~2017~~2018 represents the 13 weeks ended ~~January~~October 27, 2018 and the 13 weeks ended ~~January~~October 28, 2017, respectively. The ~~nine~~six months ended ~~January~~October 27, 2018 and ~~January~~October 28, 2017 each included 3926 weeks. Fiscal ~~2018~~2019 will include 52 weeks and fiscal ~~2017~~2018 included 52 weeks.

Comprehensive Income

Comprehensive income is computed as net income including certain other items that are recorded directly to stockholders’ equity. Significant items included in comprehensive income are foreign currency translation adjustments and the effective portion of cash flow hedges, net of tax. Foreign currency translation adjustments do not include a provision for income tax because earnings from foreign operations are considered to be indefinitely reinvested outside the U.S. The income tax expense related to cash flow hedges was ~~$265~~$173 and $265 for the three months ended ~~January~~October 27, 2018 and ~~January~~October 28, 2017, respectively. The income tax expense related to cash flow hedges was ~~$795~~$357 and ~~$792~~$530 for the ~~nine~~six months ended ~~January~~October 27, 2018 and ~~January~~October 28, 2017, respectively.

Earnings Per Share

The following table sets forth the computation of the weighted average shares outstanding used to calculate basic and diluted earnings per share ("EPS"):

Three Months Ended Nine Months Ended
January 27,
2018 January 28,
2017 January 27,
2018 January 28,
2017
Denominator for basic earnings per share – weighted average shares 91,949
94,737
92,674
95,252
Effect of dilutive securities – stock options, restricted stock and stock purchase plans 660
622
649
663
Denominator for diluted earnings per share – weighted average shares 92,609
95,359
93,323
95,915



	Three Months Ended		Six Months Ended
	October 27, 2018	October 28, 2017	October 27, 2018	October 28, 2017
Denominator for basic EPS – weighted average shares	92,683	92,722	92,606	93,037
Effect of dilutive securities – stock options, restricted stock and stock purchase plans	606	629	538	646
Denominator for diluted EPS – weighted average shares	93,289	93,351	93,144	93,683

Potentially dilutive securities representing ~~1,568~~1,890 and ~~1,354~~1,905 shares for the three and ~~nine~~six months ended ~~January~~October 27, 2018, respectively, and ~~1,499~~1,581 and ~~1,261~~1,272 shares for the three and ~~nine~~six months ended ~~January~~October 28, 2017, respectively, were excluded from the calculation of diluted ~~earnings per share~~EPS because their effects were ~~anti-dilutive.~~anti-dilutive using the treasury stock method.

Revenue Recognition

Revenues are generated from the sale of consumable products, equipment and support, software and support, technical service parts and labor, and other sources. Revenues are recognized when or as performance obligations are satisfied. Performance obligations are satisfied when the customer obtains control of the goods or services.

Consumable, equipment, software and parts sales are recorded upon delivery, except in those circumstances where terms of the sale are FOB shipping point, in which case sales are recorded upon shipment. Technical service labor is recognized as it is provided. Revenue derived from equipment and software support is recognized ratably over the period in which the support is provided.

In addition to revenues generated from the distribution of consumable products under arrangements (buy/sell agreements) where the full market value of the product is recorded as revenue, we earn commissions for services provided under agency agreements. The agency agreement contrasts to a buy/sell agreement in that we do not have control over the transaction, as we do not have the primary responsibility of fulfilling the promise of the good or service and we do not bill or collect from the customer in an agency relationship. Commissions under agency agreements are recorded when the services are provided.

Estimates for returns, damaged goods, rebates, loyalty programs and other revenue allowances are made at the time the revenue is recognized based on the historical experience for such items. The receivables that result from the recognition of revenue are reported net of related allowances. We maintain a valuation allowance based upon the expected collectability of receivables held. Estimates are used to determine the valuation allowance and are based on several factors, including historical collection data, economic trends and credit worthiness of customers. Receivables are written off when we determine the amounts to be uncollectible, typically upon customer bankruptcy or non-response to continuous collection efforts. The portions of receivable amounts that are not expected to be collected during the next twelve months are classified as long-term.

Net sales do not include sales tax as we are considered a pass-through conduit for collecting and remitting sales tax.

Contract Balances

Contract balances represent amounts presented in our condensed consolidated balance sheets when either we have transferred goods or services to the customer or the customer has paid consideration to us under the contract. These contract balances include accounts receivable, contract assets and contract liabilities.

Contract asset balances as of October 27, 2018 and April 28, 2018 were not material. Our contract liabilities primarily relate to advance payments from customers, upfront payments for software and support provided over time, and options that provide a material right to customers, such as our customer loyalty programs. At October 27, 2018 and April 28, 2018, contract liabilities of $24,386 and $26,166 were reported in other accrued liabilities, respectively. During the six months ended October 27, 2018, we recognized $15,932 of the amount previously deferred at April 28, 2018.

Recently Issued Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-09, "Revenue from Contracts with Customers (Topic 606)". ASU No. 2014-09 supersedes the revenue recognition requirements in "Revenue Recognition (Topic 605)," and requires entities to recognize revenue in a way

that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In July 2015, the FASB deferred the effective date of this pronouncement by one year to December 15, 2017 for annual reporting periods beginning after that date. Companies may use either a full retrospective or a modified retrospective approach to adopt the standard. We ~~plan to adopt~~adopted the new guidance inas of April 29, 2018 using the ~~first quarter of fiscal 2019 and are currently evaluating the standard, including the~~modified retrospective method, ~~we will use for adoption~~ and the ~~effect it will have~~adoption had no impact on ~~our financial statements. We do not expect the standard to materially affect~~ our consolidated net earnings, financial position, or cash flows. We are currently evaluating the new standard as it relates to certain sales transactions in which products are shipped directly from the vendor to our customers. We currently report these sales on a gross basis, and are evaluating if we will be required to report these sales on a net basis. Such sales represent approximately 2% of our consolidated net sales. Any change to net presentation would not impact gross margin or earnings.

In July 2015, the FASB issued ASU No. 2015-11, "Inventory (Topic 330), Simplifying the Measurement of Inventory." ASU 2015-11 requires inventory measured using any method other than LIFO or the retail inventory method to be subsequently measured at the lower of cost or net realizable value, rather than at the lower of cost or market. Subsequent measurement of inventory using the LIFO and retail inventory method is unchanged. During the first quarter of fiscal 2018, we adopted ASU No. 2015-11 and it had no material impact to the condensed consolidated financial statements.

In January 2016, the FASB issued ASU No. 2016-01 "Financial Instruments- Recognition and Measurement of Financial Assets and Financial Liabilities (Subtopic 825-10)", which amends certain aspects of recognition, measurement, presentation and disclosure of financial instruments, including the requirement to measure certain equity investments at fair value with changes in fair value recognized in net income. We ~~are required to adopt the~~adopted ASU No. 2016-01 in the first quarter of fiscal ~~2019. We are evaluating~~2019, and the adoption had no impact ~~of adopting this pronouncement.~~on our consolidated net earnings, financial position, or cash flows.

In February 2016, the FASB issued ASU No. 2016-02, "Leases (Topic 842)," which requires lessees to recognize assets and liabilities on the balance sheet for the rights and obligations created by most leases, as well as requires additional qualitative and quantitative disclosures. We are required to adopt ASU 2016-02 in the first quarter of fiscal 2020, with early adoption permitted. We plan to adopt the new guidance in the first quarter of fiscal 2020 and are currently evaluating the impact of adopting this ~~pronouncement.~~pronouncement, but anticipate that the new guidance will impact our condensed consolidated balance sheets.

In February 2018, the FASB issued ASU No. 2018-02, "Income Statement-Reporting Comprehensive Income (Topic 220) Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income," which will allow a reclassification from accumulated other comprehensive income to retained earnings for the tax effects that are stranded in accumulated other comprehensive income as a result of tax reform. This standard also requires certain disclosures about stranded tax effects. We are required to adopt ASU No. 2018-02 in the first quarter of fiscal 2020, with early adoption permitted and apply it either in the period of adoption or retrospectively to each period in which the income tax effects of the tax reform related to items in accumulated other comprehensive income are recognized. We are currently evaluating the impact of adopting this pronouncement.

Note 2. Receivables Securitization Program

On July 24, 2018, we entered into a Receivables Purchase Agreement (the “Receivables Purchase Agreement”) with MUFG Bank, Ltd. Under this agreement, MUFG Bank, Ltd. acts as an agent to facilitate the sale of certain Patterson receivables (the “Receivables”) to certain unaffiliated financial institutions (the “Purchasers”). The sale of these receivables is accounted for as a sale of assets under the provisions of ASC 860, Transfers and Servicing. We utilize PDC Funding III to facilitate the sale to fulfill requirements within the agreement.

Sales of Receivables occur daily and are settled with the Purchasers on a monthly basis. The proceeds from the sale of these Receivables comprise a combination of cash and a deferred purchase price (“DPP”) receivable. The DPP receivable is ultimately realized by Patterson following the collection of the underlying Receivables sold to the Purchasers. The amount available under the Receivables Purchase Agreement fluctuates over time based on the total amount of eligible Receivables generated during the normal course of business, with maximum availability of $200,000. As of October 27, 2018, $172,000 of the amount available under the Receivables Purchase Agreement was utilized.

We have no retained interests in the transferred Receivables, other than our right to the DPP receivable and collection and administrative services. We consider the fees received adequate compensation for services rendered, and accordingly have recorded no servicing asset or liability. The DPP receivable is recorded at fair value within the condensed consolidated balance sheets within prepaid expenses and other current assets. The DPP receivable was $58,451 as of October 27, 2018. The difference between the carrying amount of the Receivables and the sum of the cash and fair value of the DPP receivable received at time of transfer is recognized as a gain or loss on sale of the related Receivables. We recorded a loss on sale of Receivables within operating expenses in the condensed consolidated statements of income and other comprehensive income during the three and six months ended October 27, 2018 of $2,192 and $2,871, respectively.

Note 2.3. Customer Financing

As a convenience to our customers, we offer several different financing alternatives, including a third party program and a Patterson-sponsored program. For the third party program, we act as a facilitator between the customer and the third party financing entity with no on-going involvement in the financing transaction. Under the Patterson-sponsored program, equipment purchased by creditworthy customers may be financed up to a maximum of $1,000. We generally

sell our customers’ financing contracts to outside financial institutions in the normal course of our business. These financing arrangements are accounted for as a sale of assets under the provisions of ASC 860, Transfers and Servicing. We currently have two arrangements under which we sell these contracts.

First, we operate under an agreement to sell a portion of our equipment finance contracts to commercial paper conduits with MUFG Bank, Ltd. ("MUFG") (f.k.a. The Bank of Tokyo-Mitsubishi UFJ, Ltd. ~~("BTMU"~~) serving as the agent. We utilize PDC Funding to fulfill a requirement of participating in the commercial paper conduit. We receive the proceeds of the contracts upon sale to ~~BTMU.~~MUFG. At least 9.5% of the proceeds are held by the conduit as security against eventual performance of the portfolio. This percentage can be greater and is based upon certain ratios defined in the agreement with ~~BTMU.~~MUFG. The capacity under the agreement with ~~BTMU~~MUFG at ~~January~~October 27, 2018 was ~~$575,000.~~$525,000.

Second, we maintain an agreement with Fifth Third Bank ("Fifth Third") whereby Fifth Third purchases customers’ financing contracts. PDC Funding II sells its financing contracts to Fifth Third. We receive the proceeds of the contracts upon sale to Fifth Third. At least 11.0% of the proceeds are held by the conduit as security against eventual performance of the portfolio. This percentage can be greater and is based upon certain ratios defined in the agreement with Fifth Third. The capacity under the agreement with Fifth Third at ~~January~~October 27, 2018 was $100,000.

We service the financing contracts under both arrangements, for which we are paid a servicing fee. The servicing fees we receive are considered adequate compensation for services rendered. Accordingly, no servicing asset or liability has been recorded.

The portion of the purchase price for the receivables held by the conduits is deemed a ~~deferred purchase price~~DPP receivable, which is paid to the applicable special purpose entity as payments on the customers’ financing contracts are collected by Patterson from customers. The difference between the carrying amount of the receivables sold under these programs and the sum of the cash and fair value of the ~~deferred purchase price receivables~~DPP receivable received at time of transfer is recognized as a gain on sale of the related receivables and recorded in net sales in the condensed consolidated statements of income and other comprehensive income. Expenses incurred related to customer financing activities are recorded in operating expenses in our condensed consolidated statements of income and other comprehensive income.

During the three months ended ~~January~~October 27, 2018 and ~~January~~October 28, 2017, we sold ~~$45,361~~$40,713 and ~~$106,272~~$95,588 of contracts under these arrangements, respectively. During the ~~nine~~six months ended ~~January~~October 27, 2018 and ~~January~~October 28, 2017, we sold ~~$197,072~~$88,023 and ~~$278,529~~$151,711 of contracts under these arrangements, respectively. In net sales in the condensed consolidated statements of income and other comprehensive income, we recorded a ~~loss~~gain of ~~$1,688~~$2,734 and $5,967 during the three months ended ~~January~~October 27, 2018 and ~~a gain of $2,450 during the three months ended January~~October 28, 2017, respectively, related to these contracts sold. In net sales in the condensed consolidated statements of income and other comprehensive income, we recorded a gain of ~~$8,539~~$5,225 and ~~$16,966~~$10,227 during the ~~nine~~six months ended ~~January~~October 27, 2018 and ~~January~~October 28, 2017, respectively, related to these contracts sold.

Included in cash and cash equivalents in the condensed consolidated balance sheets are ~~$36,009~~$36,357 and ~~$17,902~~$35,741 as of ~~January~~October 27, 2018 and April ~~29, 2017,~~28, 2018, respectively, which represent cash collected from previously sold customer financing contracts that have not yet been settled. Included in current receivables in the condensed consolidated balance sheets are ~~$114,521,~~$66,173, net of unearned income of ~~$0,~~$7, and ~~$124,098,~~$46,232, net of unearned income of ~~$940,~~$8, as of ~~January~~October 27, 2018 and April ~~29, 2017,~~28, 2018, respectively, of finance contracts we have not yet sold. A total of ~~$581,291~~$539,426 of finance contracts receivable sold under the arrangements was outstanding at ~~January~~October 27, 2018. The ~~deferred purchase price~~DPP receivable under the arrangements was ~~$137,054~~$100,182 and ~~$119,798~~$150,404 as of ~~January~~October 27, 2018 and April ~~29, 2017,~~28, 2018, respectively. Since the internal financing program began in 1994, bad debt write-offs have amounted to less than 1% of the loans originated.

The arrangements require us to maintain a minimum current ratio and maximum leverage ratio. We were in compliance with those covenants at ~~January~~October 27, 2018.

Note 3.4. Derivative Financial Instruments

We are a party to certain offsetting and identical interest rate cap agreements entered into to fulfill certain covenants of the equipment finance contract sale agreements. The interest rate cap agreements also provide a credit enhancement feature for the financing contracts sold by PDC Funding and PDC Funding II to the commercial paper conduit.

The interest rate cap agreements are canceled and new agreements are entered into periodically to maintain consistency with the dollar maximum of the sale agreements and the maturity of the underlying financing contracts.

As of ~~January~~October 27, 2018, PDC Funding had purchased an interest rate cap from a bank with a notional amount of ~~$575,000~~$525,000 and a maturity date of July ~~2025.~~2026. We sold an identical interest rate cap to the same bank. As of ~~January~~October 27,

2018, PDC Funding II had purchased an interest rate cap from a bank with a notional amount of $100,000 and a maturity date of ~~July~~December 2025. We sold an identical interest rate cap to the same bank.

These interest rate cap agreements do not qualify for hedge accounting treatment and, accordingly, we record the fair value of the agreements as an asset or liability and the change as income or expense during the period in which the change occurs.

In March 2008, we entered into two forward starting interest rate swap agreements, each with notional amounts of $100,000 and accounted for as cash flow hedges, to hedge interest rate fluctuations in anticipation of the issuance of the senior notes due fiscal 2015 and fiscal 2018. Upon issuance of the hedged debt, we settled the forward starting interest rate swap agreements and recorded a $1,000 increase, net of income taxes, to other comprehensive income (loss), which is being amortized as a reduction to interest expense over the life of the related debt.

In January 2014, we entered into a forward interest rate swap agreement with a notional amount of $250,000 and accounted for as cash flow hedge, to hedge interest rate fluctuations in anticipation of refinancing the 5.17% senior notes due March 25, 2015. These notes were repaid on March 25, 2015 and replaced with new $250,000 3.48% senior notes due March 24, 2025. A cash payment of $29,003 was made in March 2015 to settle the interest rate swap. This amount is recorded in other comprehensive income (loss), net of tax, and is recognized as interest expense over the life of the related debt.

The following presents the fair value of derivative instruments included in the condensed consolidated balance sheets:


Derivative type	Classification	January 27, 2018		April 29, 2017		Classification	October 27, 2018		April 28, 2018
Assets:
Interest rate cap agreements	Other noncurrent assets	$	1,061	$	1,188	Other noncurrent assets	$	2,753	$	1,613
Liabilities:
Interest rate cap agreements	Other noncurrent liabilities	1,061		1,188		Other noncurrent liabilities	2,753		1,613

The following table presents the pre-tax effect of derivative instruments in cash flow hedging relationships on the condensed consolidated statements of income and other comprehensive income ("OCI"):


		Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Loss into Income (Effective Portion)													Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Loss into Income (Effective Portion)
		Three Months Ended						Nine Months Ended							Three Months Ended						Six Months Ended
Derivatives in cash flow hedging relationships	Income statement location	January 27, 2018			January 28, 2017			January 27, 2018			January 28, 2017			Income statement location	October 27, 2018			October 28, 2017			October 27, 2018			October 28, 2017
Interest rate swap	Interest expense	$	(702	)	$	(702	)	$	(2,107	)	$	(2,099	)	Interest expense	$	(725	)	$	(703	)	$	(1,458	)	$	(1,405	)

~~We recorded~~There were no ~~effective portion of~~ gains or losses recognized in OCI on ~~derivative instruments in~~ cash flow hedging ~~relationships in OCI~~derivatives during the ~~current period.~~three and six months ended October 27, 2018 or October 28, 2017.

We recorded no ineffectiveness during the three and ~~nine~~six month periods ended ~~January~~October 27, 2018 and ~~January~~October 28, 2017. As of ~~January~~October 27, 2018, the estimated pre-tax portion of accumulated other comprehensive loss that is expected to be reclassified into earnings over the next twelve months is ~~$2,885,~~$2,900, which will be recorded as an increase to interest expense.

Note 4.5. Fair Value Measurements

Fair value is the price at which an asset could be exchanged in a current transaction between knowledgeable, willing parties. The fair value hierarchy of measurements is categorized into one of three levels based on the lowest level of significant input used:

Level 1 - Quoted prices in active markets for identical assets and liabilities at the measurement date.

Level 2 - Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

~~Level 3~~ ~~- Unobservable inputs for which there is little or no market data available. These inputs reflect management’s assumptions of what market participants would use in pricing the asset or liability.~~

Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.


Level 3 -	Unobservable inputs for which there is little or no market data available. These inputs reflect management’s assumptions of what market participants would use in pricing the asset or liability.

Our hierarchy for assets and liabilities measured at fair value on a recurring basis is as follows:


	January 27, 2018								October 27, 2018
	Total		Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	3,401	$	3,401	$	—	$	—	$	64,840	$	64,840	$	—	$	—
Deferred purchase price receivable	137,054		—		—		137,054
DPP receivable - receivables securitization program									58,451		—		—		58,451
DPP receivable - customer financing									100,182		—		—		100,182
Derivative instruments	1,061		—		1,061		—		2,753		—		2,753		—
Total assets	$	141,516	$	3,401	$	1,061	$	137,054	$	226,226	$	64,840	$	2,753	$	158,633
Liabilities:
Derivative instruments	$	1,061	$	—	$	1,061	$	—	$	2,753	$	—	$	2,753	$	—


	April 29, 2017								April 28, 2018
	Total		Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	6,798	$	6,798	$	—	$	—	$	6,650	$	6,650	$	—	$	—
Deferred purchase price receivable	119,798		—		—		119,798
DPP receivable - receivables securitization program									—		—		—		—
DPP receivable - customer financing									150,404		—		—		150,404
Derivative instruments	1,188		—		1,188		—		1,613		—		1,613		—
Total assets	$	127,784	$	6,798	$	1,188	$	119,798	$	158,667	$	6,650	$	1,613	$	150,404
Liabilities:
Derivative instruments	$	1,188	$	—	$	1,188	$	—	$	1,613	$	—	$	1,613	$	—

Cash equivalents – We value cash equivalents at their current market rates. The carrying value of cash equivalents approximates fair value and maturities are less than three months.

~~Deferred purchase price~~DPP receivable - receivables securitization program – We value this DPP receivable based on a discounted cash flow analysis using unobservable inputs, which include the ~~deferred purchase price~~estimated timing of payments and the credit quality of the underlying creditor. Significant changes in any of the significant unobservable inputs in isolation would not result in a materially different fair value estimate. The interrelationship between these inputs is insignificant.

DPP receivable - customer financing – We value this DPP receivable based on a discounted cash flow analysis using unobservable inputs, which include a forward yield curve, the estimated timing of payments and the credit quality of the underlying creditor. Significant changes in any of the significant unobservable inputs in isolation would not result in a materially different fair value estimate. The interrelationship between these inputs is insignificant.

Derivative instruments – Our derivative instruments consist of interest rate cap agreements and interest rate swaps. These instruments are valued using inputs such as interest rates and credit spreads.

Certain assets are measured at fair value on a non-recurring basis. These assets are not measured at fair value on an ongoing basis, but are subject to fair value adjustments under certain circumstances, such as when there is evidence

of impairment. There were no fair value adjustments to such assets during the ~~nine~~six month ~~period~~periods ended ~~January~~October 27, ~~2018. During the nine month period ended January~~2018 or October 28, ~~2017, we recorded a non-cash impairment charge of $36,312 related to a distribution agreement intangible asset. Refer to Note 6 for more information.~~2017.

Our debt is not measured at fair value in the condensed consolidated balance sheets. The estimated fair value of our debt as of ~~January~~October 27, 2018 and April ~~29, 2017~~28, 2018 was ~~$1,013,300~~$800,636 and ~~$1,025,761,~~$989,124, respectively, as compared to a carrying value of ~~$1,006,173~~$818,627 and ~~$1,013,026~~$998,628 at ~~January~~October 27, 2018 and April ~~29, 2017,~~28, 2018, respectively. The fair value of debt was measured using a discounted cash flow analysis based on expected market based yields (i.e., ~~level~~Level 2 inputs).

The carrying amounts of receivables, net of allowances, accounts payable, and certain accrued and other current liabilities approximated fair value at ~~January~~October 27, 2018 and April ~~29, 2017.~~28, 2018.

Note 5.6. Income Taxes

The effective income tax rate for the three months ended ~~January~~October 27, 2018 was ~~(170.0)%~~24.0% compared to ~~23.2%~~34.5% for the three months ended ~~January~~October 28, 2017, and for the ~~nine~~six months ended ~~January~~October 27, 2018 was ~~(20.9)%~~25.1% compared to ~~31.9%~~34.5% for the ~~nine~~six months ended ~~January~~October 28, 2017.

The change in tax ~~benefit~~rate for the three ~~and nine~~ months ended ~~January~~October 27, 2018 compared to the three months ended October 28, 2017 was primarily due to the impact of the Tax Cuts and Jobs Act ("Tax Act"), enacted on December 22, 2017 by the U.S. ~~government.~~government . The change in tax rate for the six months ended October 27, 2018 compared to the six months ended October 28, 2017 was primarily due to the impact of the Tax Act and lower excess tax benefits on employee share-based compensation. The Tax Act significantly revises the future ongoing U.S. federal corporate income tax by, among other things, lowering U.S. federal corporate tax rates and implementing a territorial tax system. Effective January 1, 2018, the Tax Act reduced the U.S. federal corporate tax rate from 35.0% to 21.0%. For ~~our~~the fiscal year ~~ending~~ended April 28, 2018, we ~~will utilize~~utilized a blended rate of approximately 30.5%. For the ~~quarter~~three and six months ended ~~January~~October 27, 2018, ~~these impacts resulted in~~we utilized a ~~provisional discrete net tax benefit of $77,256, which included provisional amounts of $81,206 of tax benefit on~~21.0% U.S. ~~deferred tax assets and liabilities and $3,950 of tax expense for a one-time transition tax on unremitted foreign earnings.~~federal statutory rate.

The legislative changes included in the Tax Act are broad and complex. ~~We determined that~~For the fiscal year ended April 28, 2018, we recognized provisional net tax benefit of $76,648, which included provisional amounts of $81,871 of tax benefit on U.S. deferred tax assets and liabilities, $4,006 of tax expense for a one-time transition tax on unremitted foreign earnings isand $1,217 in withholding taxes paid on current year distributions. During the six months ended October 27, 2018, there were no changes made to the provisional ~~because various components~~amounts recognized in fiscal year 2018. We continue to analyze the effects of the ~~computation~~Tax Act and will record additional impacts as they are ~~unknown as~~identified. Staff Accounting Bulletin No. 118 provides for a measurement period of ~~January 27, 2018. In addition, we determined that~~up to one year from the enactment date. The final impact of the ~~U.S. federal corporate income tax rate change on~~Tax Act may differ from the ~~U.S. deferred tax assets and liabilities is~~ provisional ~~because the amount cannot be calculated until the underlying timing differences are known rather than estimated.~~

Given the Tax Act’s significant changes and potential opportunities to repatriate cash tax free, we are in the process of evaluating our current indefinite assertions with regard to cash and earningsamounts that have been ~~subjected~~recognized.

For the fiscal year ended April 28, 2018, and directly connected to the transition ~~tax. We continue~~tax legislation, Patterson approved a one-time repatriation of cash included in the transition tax computation. There was an approximate $1,217 one-time cost recorded during fiscal 2018 to reflect the added withholding tax cost associated with this repatriation. With the exception of this one-time repatriation, Patterson continues to apply ASC 740 based on the provisions of the tax law that were in effect immediately prior to the enactment of the ~~Tax Act.~~new law. With regard to unremitted earnings of foreign subsidiaries ~~that have not been previously taxed,~~generated after December 31, 2017, we do not currently provide for U.S. taxes since we intend to invest such undistributed earnings indefinitely outside of the U.S.

We continue to review the ~~anticipated impacts~~impact of the global intangible low taxed income (“GILTI”) ~~and base erosion and anti-abuse tax (“BEAT”)~~ provisions under the Tax Act which are ~~not effective until fiscal year 2019. We~~complex and subject to continued regulatory interpretation by the IRS. While we have ~~not recorded any impact associated with either~~included an estimate of GILTI ~~or BEAT~~ in the effective tax rate for the three and six months ended ~~January~~October 27, ~~2018.~~2018, we have not yet completed our analysis.

The final transition impacts of the Tax Act may differ from the above ~~estimate,~~estimates, possibly materially, due to, among other things, changes in interpretations of the Tax Act, any federal and/or state legislative action to address questions that arise because of the Tax Act, any changes in accounting standards for income taxes or related interpretations in response to the Tax Act, or any updates or changes to estimates we have utilized to calculate the transition ~~impacts, including impacts from changes to current year earnings estimates and foreign exchange rates of foreign subsidiaries.~~impacts. The Securities and Exchange Commission has issued rules, under SAB 118, that will allow for a measurement period of up to one year after the enactment date of the Tax Act to finalize the recording of the related tax impacts.

Note ~~6. Intangible Asset Impairment~~7. Technology Partner Innovations, LLC

In 2006, we extended our exclusive North American distribution relationship with Sirona Dental Systems for Sirona’s CEREC 3D dental restorative system. At that time, we paid a $100,000 distribution fee to extend the ~~existing exclusive relationship for at least a 10-year period beginning in 2007. This distribution fee was accounted for as an intangible asset and amortized since 2007.~~

Based on our November 2016 decision not to extend sales exclusivity for the full Sirona portfolio of products, we recorded a pre-tax non-cash impairment charge of $36,312 in our Dental segment in the thirdfirst quarter of fiscal ~~2017, related~~2019, we entered into an agreement with Cure Partners to form Technology Partner Innovations, LLC (TPI), which is launching a new cloud-based practice management software, NaVetor. Patterson and Cure Partners each contributed net assets of $4,000 to form TPI. We have determined that TPI is a variable interest entity, and we consolidate the results of operations of TPI as we have concluded that we are the primary beneficiary of TPI. During the three and six ended October 27, 2018, net loss attributable to the ~~distribution fee associated with the CEREC product component~~noncontrolling interest was $223 and $276, respectively, resulting in noncontrolling interests of ~~this arrangement. This charge was recorded within operating expenses in~~$3,724 on the condensed consolidated ~~statements of income and other comprehensive income.~~balance sheet at October 27, 2018.

Note 7.8. Segment ~~Reporting~~and Geographic Data

dentists, dental laboratories, institutions, and other healthcare professionals throughout North America. Animal Health is a leading, full-line distributor in North America and the U.K. of animal health products, services and technologies to both the production-animal and companion-pet markets. Our Corporate segment is comprised of general and administrative expenses, including home office support costs in areas such as information technology, finance, legal, human resources and facilities. In addition, customer financing and other miscellaneous sales are reported within Corporate results. Corporate assets consist primarily of cash and cash equivalents, accounts receivable, property and equipment and long-term receivables. We evaluate segment performance based on operating income. The costs to operate the fulfillment centers are allocated to the operating units based on the through-put of the unit.

The following ~~table presents~~tables present information about our reportable segments:

Three Months Ended Nine Months Ended
January 27,
2018 January 28,
2017 January 27,
2018 January 28,
2017
Net sales
Dental $ 577,877
$ 626,343
$ 1,650,314
$ 1,782,911
Animal Health 794,867
762,577
2,394,586
2,332,354
Corporate 2,478
8,498
20,174
32,830
Consolidated net sales $ 1,375,222
$ 1,397,418
$ 4,065,074
$ 4,148,095
Operating income (loss) from continuing operations
Dental $ 58,439
$ 40,018
$ 183,165
$ 177,356
Animal Health 18,037
23,777
57,930
60,460
Corporate (26,430 ) (17,241 ) (62,457 ) (46,043 )
Consolidated operating income from continuing operations $ 50,046
$ 46,554
$ 178,638
$ 191,773



	Three Months Ended				Six Months Ended
	October 27, 2018		October 28, 2017		October 27, 2018		October 28, 2017
Consolidated net sales
United States	$	1,173,623	$	1,151,380	$	2,270,087	$	2,231,707
United Kingdom	150,452		148,734		304,357		289,588
Canada	80,677		85,623		166,628		168,557
Total	$	1,404,752	$	1,385,737	$	2,741,072	$	2,689,852
Dental net sales
United States	$	495,457	$	500,803	$	949,030	$	967,491
Canada	47,059		52,827		99,550		104,946
Total	$	542,516	$	553,630	$	1,048,580	$	1,072,437
Animal Health net sales
United States	$	671,338	$	642,053	$	1,309,187	$	1,246,520
United Kingdom	150,452		148,734		304,357		289,588
Canada	33,618		32,796		67,078		63,611
Total	$	855,408	$	823,583	$	1,680,622	$	1,599,719
Corporate net sales
United States	$	6,828	$	8,524	$	11,870	$	17,696
Total	$	6,828	$	8,524	$	11,870	$	17,696

January 27,
2018 April 29,
2017
Total assets
Dental $ 953,273
$ 863,970
Animal Health 2,196,733
2,119,512
Corporate 524,352
524,431
Total assets $ 3,674,358
$ 3,507,913



	Three Months Ended				Six Months Ended
	October 27, 2018		October 28, 2017		October 27, 2018		October 28, 2017
Consolidated net sales
Consumable	$	1,138,251	$	1,116,091	$	2,247,648	$	2,196,196
Equipment and software	182,120		181,337		329,018		318,286
Other	84,381		88,309		164,406		175,370
Total	$	1,404,752	$	1,385,737	$	2,741,072	$	2,689,852
Dental net sales
Consumable	$	303,806	$	311,217	$	608,045	$	631,395
Equipment and software	167,686		169,513		302,643		297,376
Other	71,024		72,900		137,892		143,666
Total	$	542,516	$	553,630	$	1,048,580	$	1,072,437
Animal Health net sales
Consumable	$	834,445	$	804,874	$	1,639,603	$	1,564,801
Equipment and software	14,434		11,824		26,375		20,910
Other	6,529		6,885		14,644		14,008
Total	$	855,408	$	823,583	$	1,680,622	$	1,599,719
Corporate net sales
Other	$	6,828	$	8,524	$	11,870	$	17,696
Total	$	6,828	$	8,524	$	11,870	$	17,696

~~The following table presents sales information by product for all of our reportable segments:~~

Three Months Ended Nine Months Ended
January 27,
2018 January 28,
2017 January 27,
2018 January 28,
2017
Net sales
Consumable $ 1,074,189
$ 1,064,098
$ 3,270,385
$ 3,252,551
Equipment and software 222,574
249,047
540,860
627,187
Other 78,459
84,273
253,829
268,357
Consolidated net sales $ 1,375,222
$ 1,397,418
$ 4,065,074
$ 4,148,095



	Three Months Ended						Six Months Ended
	October 27, 2018			October 28, 2017			October 27, 2018			October 28, 2017
Operating income (loss)
Dental	$	41,594		$	65,207		$	77,467		$	124,726
Animal Health	22,031			23,217			41,063			39,893
Corporate	(22,409		)	(16,665		)	(72,800		)	(36,027		)
Consolidated operating income	$	41,216		$	71,759		$	45,730		$	128,592



	October 27, 2018		April 28, 2018
Total assets
Dental	$	668,603	$	853,555
Animal Health	2,158,144		2,128,800
Corporate	517,507		489,309
Total assets	$	3,344,254	$	3,471,664

Note 8.9. Accumulated Other Comprehensive Loss ("AOCL")

The following table summarizes the changes in AOCL as of ~~January~~October 27, 2018:


	Cash Flow Hedges			Currency Translation Adjustment			Total			Cash Flow Hedges			Currency Translation Adjustment			Total
AOCL at April 29, 2017	$	(14,989	)	$	(77,680	)	$	(92,669	)
AOCL at April 28, 2018										$	(13,118	)	$	(61,856	)	$	(74,974	)
Other comprehensive loss before reclassifications	—			24,594			24,594			—			(12,860		)	(12,860		)
Amounts reclassified from AOCL	1,312			—			1,312			1,101			—			1,101
AOCL at January 27, 2018	$	(13,677	)	$	(53,086	)	$	(66,763	)
AOCL at October 27, 2018										$	(12,017	)	$	(74,716	)	$	(86,733	)

The amounts reclassified from AOCL during fiscal ~~2018~~2019 represent gains and losses on cash flow hedges, net of taxes of ~~$795.~~$357. The impact to the condensed consolidated statements of income and other comprehensive income was an increase to interest expense of ~~$2,107.~~$1,458.

Note 9.10. Legal Proceedings

In September 2015, we were served with a summons and complaint in an action commenced in the U.S. District Court for the Eastern District of New York, entitled SourceOne Dental, Inc. v. Patterson Companies, Inc., Henry Schein, Inc. and Benco Dental Supply Company, Civil Action No. 15-cv-05440-JMA-GRB. SourceOne, as plaintiff, alleges that, through its website, it markets and sells dental supplies and equipment to dentists. SourceOne alleges in the complaint, among other things, that we, along with the defendants Henry Schein and Benco, conspired to eliminate plaintiff as a competitor and to exclude them from the market for the marketing, distribution and sale of dental supplies and equipment in the U.S. and that defendants unlawfully agreed with one another to boycott dentists, manufacturers, and state dental associations that deal with, or considered dealing with, plaintiff. Plaintiff asserts the following claims: (i) unreasonable restraint of trade in violation of state and federal antitrust laws; (ii) tortious interference with prospective business relations; (iii) civil conspiracy; and (iv) aiding and abetting the other defendants’ ongoing tortious and anticompetitive conduct. Plaintiff seeks equitable relief, compensatory and treble damages, jointly and severally, punitive damages, interest, and reasonable costs and expenses, including attorneys’ fees and expert fees. In June 2017, Henry Schein settled with SourceOne and was dismissed from this litigation with prejudice. We are vigorously defending ourselves in this litigation. Trial is scheduled to begin on April 29, 2019. We do not anticipate that this matter will have a material adverse effect on our financial statements.

Beginning in January 2016, purported antitrust class action complaints were filed against defendants Henry Schein, Inc., Benco Dental Supply Company and Patterson Companies, Inc. Although there were factual and legal variations among these complaints, each alleged that defendants conspired to foreclose and exclude competitors by boycotting manufacturers, state dental associations, and others that deal with defendants’ competitors. On February 9, 2016, the U.S. District Court for the Eastern District of New York ordered all of these actions, and all other actions filed thereafter asserting substantially similar claims against defendants, consolidated for pre-trial purposes. On February 26, 2016, a consolidated class action complaint was filed by Arnell Prato, D.D.S., P.L.L.C., d/b/a Down to Earth Dental, Evolution Dental Sciences, LLC, Howard M. May, DDS, P.C., Casey Nelson, D.D.S., Jim Peck, D.D.S., Bernard W. Kurek, D.M.D., Larchmont Dental Associates, P.C., and Keith Schwartz, D.M.D., P.A. (collectively, “putative class representatives”) in the U.S. District Court for the Eastern District of New York, entitled In re Dental Supplies Antitrust Litigation, Civil Action No. 1:16-CV-00696-BMC-GRB. Subject to certain exclusions, the putative class representatives seek to represent all ~~persons~~private dental practices and laboratories who purchased dental supplies or equipment in the U.S. directly from any of the defendants, ~~since~~during the period beginning August 31, ~~2008.~~2008 until March 31, 2016. In the consolidated class action complaint, putative class representatives allege a nationwide agreement among Henry Schein, Benco, Patterson and non-party Burkhart Dental Supply Company, Inc. not to compete on price. The consolidated class action complaint asserts a single count under Section 1 of the Sherman Act, and seeks equitable relief, compensatory and treble damages, jointly and severally, interest, and reasonable costs and expenses, including attorneys’ fees and expert fees. ~~While~~On September 28, 2018, the ~~outcome~~parties executed a settlement agreement that proposes a full and final settlement of ~~litigation is inherently uncertain,~~the lawsuit on a class-wide basis, subject to court approval. Related to this settlement, we ~~believe the consolidated class action complaint is without merit, and we are vigorously defending ourselves~~recorded a charge of $28,263 in ~~this litigation.~~our first quarter 2019 results in our Corporate segment.

to join a price-fixing conspiracy and boycott by reducing the distribution territory of, and eventually terminating, Archer. Archer seeks injunctive relief, and damages in an amount to be proved at trial, to be trebled with interest and costs, including attorneys’ fees, jointly and severally. On ~~March 2,~~June 25, 2018, ~~the case was stayed by~~ the United States Supreme Court ~~pending its decision as to whether~~granted certiorari to review an arbitration issue raised by the Danaher ~~Defendants.~~Defendants, thereby continuing the case stay implemented in March 2018. On October 29, 2018, the United States Supreme Court heard oral argument. The United States Supreme Court’s decision is pending. We are vigorously defending ourselves in this litigation. We do not anticipate that this matter will have a material adverse effect on our financial statements.

On August 17, 2017, IQ Dental Supply, Inc. (“IQ Dental”) filed a complaint in the United States District Court for the Eastern District of New York, entitled IQ Dental Supply, Inc. v. Henry Schein, Inc., Patterson Companies, Inc. and Benco Dental Supply Company, Case No. 2:17-cv-4834. Plaintiff alleges that it is a distributor of dental supplies and equipment, and sells dental products through an online dental distribution platform operated by SourceOne Dental, Inc. IQ Dental alleges, among other things, that defendants conspired to suppress competition from IQ Dental and SourceOne for the marketing, distribution and sale of dental supplies and equipment in the United States, and that defendants unlawfully agreed with one another to boycott dentists, manufacturers and state dental associations that deal with, or considered dealing with, plaintiff and SourceOne. Plaintiff claims that this alleged conduct constitutes unreasonable restraint of trade in violation of Section 1 of the Sherman Act, New York’s Donnelly Act and the New Jersey Antitrust Act, and also makes pendant state law claims for tortious interference with prospective business relations, civil conspiracy and aiding and abetting. Plaintiff seeks injunctive relief, compensatory, treble and punitive damages, jointly and severally, and reasonable costs and expenses, including attorneys’ fees and expert fees. On December 21, 2017, the District Court granted defendants motion to dismiss the complaint with prejudice. Plaintiff has appealed to the ~~Fifth Circuit~~District Court’s order. The U.S. Court of ~~Appeals.~~Appeals for the Second Circuit heard oral argument on the appeal on September 13, 2018. The court’s decision is pending. We are vigorously defending ourselves in this litigation. We do not anticipate that this matter will have a material adverse effect on our financial statements.

obtain supply agreements on behalf of groups of solo practitioners or small group dental practices. The administrative complaint seeks injunctive relief against Patterson, including an order to cease and desist from the conduct alleged in the complaint and a prohibition from conspiring or agreeing with any competitor or any person to refuse to provide discounts to or compete for the business of any customer. No money damages are sought. We ~~intend to~~are vigorously ~~defend~~defending ourselves against the administrative complaint. The ~~administrative complaint provides notice of an October 16, 2018~~ hearing in front of an Administrative Law Judge of the FTC in Washington, D.C. began on October 16, 2018 and is ongoing. We do not anticipate this matter will have a material adverse effect on our financial statements.

On March 28, 2018, Plymouth County Retirement System (“Plymouth”) filed a federal securities class action complaint against Patterson Companies, Inc. and its former CEO Scott P. Anderson and former CFO Ann B. Gugino in the U.S. District Court for the District of Minnesota in a case captioned Plymouth County Retirement System v. Patterson Companies, Inc., Scott P. Anderson and Ann B. Gugino, Case No. 0:18-cv-00871 MJD/SER. On November 9, 2018, the complaint was amended to add former CEO James W. Wiltz and former CFO R. Stephen Armstrong as individual defendants. Under the amended complaint, on behalf of all persons or entities that purchased or otherwise acquired Patterson’s common stock between June 26, 2013 and February 28, 2018, Plymouth alleges that Patterson violated federal securities laws by failing to disclose that Patterson’s revenue and earnings were “artificially inflated by Defendants’ illicit, anti-competitive scheme with its purported competitors, Benco and Schein, to prevent the formation of buying groups that would allow its customers who were office-based practitioners to take advantage of pricing arrangements identical or comparable to those enjoyed by large-group customers.” In its class action complaint, Plymouth asserts one count against Patterson for violating Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder and a second, related count against the individual defendants for violating Section 20(a) of the Exchange Act. Plymouth seeks compensatory damages, pre- and post-judgment interest and reasonable attorneys’ fees and experts’ witness fees and costs. On August 30, 2018, Gwinnett County Public Employees Retirement System and Plymouth County Retirement System, Pembroke Pines Pension Fund for Firefighters and Police Officers, Central Laborers Pension Fund were appointed lead plaintiffs. While the outcome of litigation is inherently uncertain, we believe that the class action complaint is without merit, and we are vigorously defending ourselves in this litigation. We do not anticipate that this matter will have a material adverse effect on our financial statements. Patterson has also received requests under Minnesota Business Corporation Act § 302A.461 to inspect corporate books and records relating to the issues raised in the securities class action and the antitrust matters discussed above.

During the first quarter of fiscal 2019, the U.S. Attorney’s Office for the Western District of Virginia informed us that our subsidiary, Animal Health International, Inc., has been designated a target of a criminal investigation. The main focus of the investigation to date and the alleged relationships at issue occurred prior to our acquisition of Animal Health International in June 2015 and relate to legacy Animal Health International sales of prescription animal health products to certain persons and/or locations not licensed to receive them in Virginia and Tennessee in violation of federal and state laws. In October 2018, we entered into a tolling agreement effective for three months to allow us to produce documents responsive to grand jury subpoenas and to allow for further evaluation of evidence. We also are conducting an internal investigation and are cooperating with the U.S. Attorney’s Office. At this time, we are unable to make an estimate of the amount of loss, if any, or range of possible loss that we could incur as a result of the foregoing matter.

On August 28, 2018, Kirsten Johnsen filed a stockholder derivative complaint against Patterson Companies, Inc., as a nominal defendant, and the following former and current officers and directors of Patterson: Scott Anderson, Ann Gugino, James Wiltz, John Buck, Jody Feragen, Ellen Rudnick, Les Vinney, Neil Schrimsher, Sarena Lin, Harold Slavkin, Alex Blanco and Mark Walchirk as individual defendants in Hennepin County District Court in a case captioned Kirsten Johnsen v. Scott P. Anderson et al., Case No. 27-CV-18-14315. Derivatively on behalf of Patterson, plaintiff alleges that Patterson “suppressed price competition and maintained supracompetitive prices for dental supplies and equipment by entering into agreements with Henry Schein and Benco to: (i) fix margins for dental supplies and equipment; and (ii) block the entry and expansion of lower-margin, lower-priced, rival dental distributors through threatened and actual group boycotts.” Plaintiff further alleges that the individual defendants failed to disclose Patterson’s alleged “price-fixing scheme” to the public and purportedly “caused Patterson to repurchase over $412,800 worth of its own stock at artificially inflated prices.” In the derivative complaint, plaintiff asserts three counts against the individual defendants for: (i) breach of fiduciary duty; (ii) waste of corporate assets; and (iii) unjust enrichment. Plaintiff seeks compensatory damages, equitable and injunctive relief as permitted by law, costs, disbursements and reasonable attorneys’ fees, accountants’ fees and experts’ fees, costs and expenses, and an order awarding restitution from the individual defendants and directing Patterson “to take all necessary actions to reform and improve its corporate governance and internal procedures.” While the outcome of litigation is inherently uncertain, we believe that the

derivative complaint is without merit, and we intend to vigorously defend ourselves in this litigation. We do not anticipate that this matter will have a material adverse effect on our financial statements.

On October 1, 2018, Sally Pemberton filed a stockholder derivative complaint against Patterson Companies, Inc., as a nominal defendant, and the following former and current officers and directors of Patterson: Scott Anderson, Ann Gugino, Mark Walchirk, John Buck, Alex Blanco, Jody Feragen, Sarena Lin, Ellen Rudnick, Neil Schrimsher, Les Vinney, James Wiltz, Paul Guggenheim, David Misiak and Tim Rogan as individual defendants in the United States District Court for the District of Minnesota in a case captioned Sally Pemberton v. Scott P. Anderson, et al., Case No. 18-CV-2818. Derivatively on behalf of Patterson, plaintiff alleges that Patterson, with Benco and Henry Schein, “engage[d] in a conspiracy in restraint of trade, whereby the companies agreed to refuse to offer discounted prices or otherwise negotiate with GPOs, agreed to fix margins on dental supplies and equipment, agreed not to poach one another’s customers or sales representatives, and agreed to block the entry and expansion of rival distributors. Plaintiff further alleges that the individual defendants failed to disclose Patterson’s alleged “antitrust misconduct” to the public and purportedly caused Patterson to repurchase $412,800 of its own stock at prices that were artificially inflated. In the derivative complaint, plaintiff asserts six counts against the individual defendants for: (i) breach of fiduciary duty; (ii) waste of corporate assets; (iii) unjust enrichment; (iv) violations of Section 14(a) of the Exchange Act; (v) violations of Section 10(b) and Rule 10b-5 of the Exchange Act and (vi) violations of Section 20(a) of the Exchange Act. Plaintiff seeks compensatory damages with pre-judgment and post-judgment interest, costs, disbursements and reasonable attorneys’ fees, experts’ fees, costs and expenses, and an order awarding restitution from the individual defendants and directing Patterson “to take all necessary actions to reform and improve its corporate governance and internal procedures.” While the outcome of litigation is inherently uncertain, we believe that the derivative complaint is without merit, and we intend to vigorously defend ourselves in this litigation. We do not anticipate that this matter will have a material adverse effect on our financial statements.

On October 9, 2018, Nathaniel Kramer filed indirect purchaser litigation against Patterson Companies, Inc., Henry Schein, Inc. and Benco Dental Supply Company in the United States District Court for the District of Northern District of California. The purported class action complaint asserts violations of the California Cartwright Act and the California Unfair Competition Act based on an alleged agreement between Schein, Benco, and Patterson (and unnamed co-conspirators) not to compete as to price and margins. Plaintiff alleges that the agreement allowed the defendants to charge higher prices to dental practices for dental supplies and that the dental practices passed on all, or part of, the increased prices to the consumers of dental services. Subject to certain exclusions, the complaint defines the class as all persons residing in California purchasing and/or reimbursing for dental services from California dental practices. The complaint seeks a permanent injunction, actual damages to be determined at trial, trebled, reasonable attorneys’ fees and costs, and pre- and post-judgment interest. While the outcome of litigation is inherently uncertain, we believe that the derivative complaint is without merit, and we intend to vigorously defend ourselves in this litigation.

While management currently believes that resolving all of these matters, individually or in the aggregate, will not have a material adverse effect on our financial statements, the litigation and other claims noted above are subject to inherent uncertainties and management’s view of these matters may change in the future. Adverse outcomes in some or all of the claims pending against us may result in significant monetary damages or injunctive relief against us that could adversely affect our ability to conduct our business. There also exists the possibility of a material adverse effect on our financial statements for the period in which the effect of an unfavorable final outcome becomes probable and reasonably estimable.

From time to time, we may become a party to other legal proceedings, including, without limitation, product liability claims, intellectual property claims, employment matters, commercial disputes, governmental inquiries and investigations (which may in some cases involve our entering into settlement arrangements or consent decrees), and other matters arising out of the ordinary course of our business. While the results of any legal proceeding cannot be predicted with certainty, in our opinion none of these other pending matters is anticipated to have a material adverse effect on our financial statements.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This Form 10-Q for the period ended ~~January~~October 27, 2018, contains certain forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are information of a non-historical nature and are subject to risks and uncertainties that are beyond Patterson’s ability to control. Forward-looking statements

generally can be identified by words such as “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates” or other words or phrases of similar import. It is uncertain whether any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do, what impact they will have on the results of operations and financial condition of Patterson or the price of Patterson stock. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially from those indicated in such forward-looking statements. Such risks and uncertainties include, without limitation, the cautionary language set forth herein; operations disruptions attributable to our enterprise resource planning system implementation; our ability to attract or retain qualified sales representatives and service technicians who relate directly with our customers; the reduction,

modification, cancellation or delay of purchases of innovative, high-margin equipment; material changes in our purchasing relationships with suppliers; changes in general market and economic conditions; and the other risks and important factors contained and identified in Patterson’s previous filings with the Securities and Exchange Commission, such as its Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K, any of which could cause actual results to differ materially from the forward-looking statements.

OVERVIEW

Our financial information for the first ~~nine~~six months of fiscal ~~2018~~2019 is summarized in this Management’s Discussion and Analysis and the Condensed Consolidated Financial Statements and related Notes. The following background is provided to readers to assist in the review of our financial information.

We present three reportable segments: Dental, Animal Health and Corporate. Dental and Animal Health are strategic business units that offer similar products and services to different customer bases. Dental provides a virtually complete range of consumable dental products, equipment and software, turnkey digital solutions and value-added services to dentists and dental laboratories throughout North America. Animal Health is a leading, full-line distributor in North America and the U.K. of animal health products, services and technologies to both the production-animal and companion-pet markets. Our Corporate segment is comprised of general and administrative expenses, including home office support costs in areas such as information technology, finance, legal, human resources and facilities. In addition, customer financing and other miscellaneous sales are reported within Corporate results.

Operating margins of the animal health business are considerably lower than the dental business. While operating expenses run at a lower rate in the animal health business when compared to the dental business, gross margins in the animal health business are substantially lower due generally to the low margins experienced on the sale of pharmaceutical products.

We operate with a 52-53 week accounting convention with our fiscal year ending on the last Saturday in April. The ~~third~~second quarter of fiscal ~~2018~~2019 and ~~2017~~2018 represents the 13 weeks ended ~~January~~October 27, 2018 and the 13 weeks ended ~~January~~October 28, 2017, respectively. ~~The nine months ended January 27, 2018 and January 28, 2017 each included 39 weeks.~~ Fiscal ~~2018~~2019 will include 52 weeks and fiscal ~~2017~~2018 included 52 weeks.

We believe there are several important aspects of our business that are useful in analyzing it, including: (1) growth in the various markets in which we operate; (2) internal growth; (3) growth through acquisition; and (4) continued focus on controlling costs and enhancing efficiency. Management defines internal growth as the increase in net sales from period to period, adjusting for differences in the number of weeks in fiscal years, excluding the impact of changes in currency exchange rates, and excluding the net sales, for a period of twelve months following the transaction date, of businesses we have acquired.

FACTORS AFFECTING OUR RESULTS

~~Enterprise Resource Planning System Initiatives.~~ In the third quarter of fiscal 2017, we completed the application development stage of our enterprise resource planning ("ERP") system, and we began depreciating our investment in such system. We incurred lower operating expenses of approximately $5.0 million in the three months ended January 27, 2018 as compared to the three months ended January 28, 2017 related to this implementation. We incurred increased depreciation and other operating expenses of approximately $6.0 million in the nine months ended January 27, 2018 as compared to the nine months ended January 28, 2017 related to this implementation.

~~Intangible Asset Impairment.~~ In 2006, we extended our exclusive North American distribution relationship with Sirona Dental Systems for Sirona’s CEREC 3D dental restorative system. At that time, we paid a $100.0 million distribution fee to extend the existing exclusive relationship for at least a 10-year period beginning in 2007. This distribution fee was accounted for as an intangible asset and amortized since 2007. Based on our November 2016 decision not to extend sales exclusivity for the full Sirona portfolio of products, we recorded a pre-tax non-cash impairment charge of $36.3 million, or $23.0 million after taxes or $0.24 per diluted share in our Dental segment in the third quarter of fiscal 2017, related to the distribution fee associated with the CEREC product component of this arrangement.

U.S. Tax ~~Reform.~~ Reform. On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (“Tax Act”). The Tax Act significantly revises the future ongoing U.S. federal corporate income tax by, among other things, lowering U.S. federal corporate tax rates and implementing a territorial tax system. Effective January 1, 2018, the Tax Act reduced the U.S. federal corporate tax rate from 35.0% to 21.0%.

~~For our fiscal year ending April 28,~~Receivables Securitization Program. On July 24, 2018, we ~~will utilize~~entered into a ~~blended rate~~receivables purchase agreement with MUFG Bank, Ltd. Under this agreement, MUFG Bank, Ltd. acts as an agent to facilitate the sale of ~~approximately 30.5%~~certain Patterson receivables (the “Receivables”) to certain unaffiliated financial institutions (the “Purchasers”). ~~For~~

The proceeds from the ~~quarter ended January 27, 2018,~~sale of these ~~impacts resulted in~~Receivables comprise a ~~provisional discrete net tax benefit~~combination of ~~$77.3 million, which included provisional amounts~~cash and a deferred purchase price (“DPP”) receivable. The initial transaction was a sale of ~~$81.2~~$237.6 million of ~~tax benefit on U.S. deferred tax assets and liabilities and $4.0~~net receivables. From this sale, we received $171.0 million of ~~tax expense~~cash and a DPP receivable with a fair value of $65.9 million. In addition, we recorded a loss of $0.7 million as a result of this transaction. The proceeds from the initial sale were primarily used to reduce debt.

The DPP receivable is ultimately realized by Patterson following the collection of the underlying Receivables sold to the Purchasers. The collection of the DPP receivable is recognized as an increase to net cash provided by investing activities within the condensed consolidated statements of cash flows, with a corresponding reduction to net cash provided by operating activities within the condensed consolidated statements of cash flows.

Legal Reserve. In September 2018, we signed an agreement to settle the litigation entitled In re Dental Supplies Antitrust Litigation. Under the terms of the settlement, we will pay $28.3 million upon final court approval. We previously established a pre-tax reserve of $28.3 million ("Legal Reserve") during the first quarter of fiscal 2019 to account for ~~a one-time transition tax on unremitted foreign earnings.~~the settlement of this matter. The settlement remains subject to preliminary and final court approval.

RESULTS OF OPERATIONS

QUARTER ENDED ~~JANUARY~~OCTOBER 27, 2018 COMPARED TO QUARTER ENDED ~~JANUARY~~OCTOBER 28, 2017

~~Continuing Operations~~

The following table summarizes our results ~~from continuing operations~~ as a percent of net ~~sales from continuing operations:~~sales:


	Three Months Ended				Three Months Ended
	January 27, 2018		January 28, 2017		October 27, 2018		October 28, 2017
Net sales	100.0	%	100.0	%	100.0	%	100.0	%
Cost of sales	78.6		76.4		79.0		77.2
Gross profit	21.4		23.6		21.0		22.8
Operating expenses	17.8		20.3		18.1		17.6
Operating income from continuing operations	3.6		3.3
Operating income					2.9		5.2
Other income (expense)	(0.7	)	(0.7	)	(0.2	)	(0.8	)
Income from continuing operations before taxes	2.9		2.6
Income tax expense (benefit)	(5.0	)	0.6
Net income from continuing operations	7.9	%	2.0	%
Income before taxes					2.7		4.4
Income tax expense					0.7		1.5
Net income					2.0		2.9
Net loss attributable to noncontrolling interests					—		—
Net income attributable to Patterson Companies, Inc.					2.0	%	2.9	%

Net Sales. Consolidated net sales for the three months ended ~~January~~October 27, 2018 were ~~$1,375.2~~$1,404.8 million, ~~a decrease~~an increase of ~~1.6%~~1.4% from ~~$1,397.4~~$1,385.7 million for the three months ended ~~January~~October 28, 2017. Foreign exchange rate changes had ~~a favorable~~an unfavorable impact of ~~1.1%~~0.3% on current quarter sales.

Dental segment sales for the three months ended ~~January~~October 27, 2018 were ~~$577.9~~$542.5 million, a decrease of ~~7.7%~~2.0% from ~~$626.3~~$553.6 million for the three months ended ~~January~~October 28, 2017. Foreign exchange rate changes had ~~a favorable~~an unfavorable impact of ~~0.4%~~0.2% on current quarter sales. Current quarter sales of consumables decreased ~~7.0%~~2.4%, sales of dental equipment and software decreased ~~10.2%~~1.1% to ~~$207.0~~$167.7 million, and sales of other dental services and products decreased ~~3.0%~~2.6%. The decrease in sales of consumables was mainly due to changes in our sales force and disruptions resulting from our ERP system initiatives.

Animal Health segment sales for the three months ended ~~January~~October 27, 2018 were ~~$794.9~~$855.4 million, an increase of ~~4.2%~~3.9% from ~~$762.6~~$823.6 million for the three months ended ~~January~~October 28, 2017. Foreign exchange rate changes had ~~a favorable~~an unfavorable impact of ~~1.6%~~0.4% on current quarter sales. Sales of certain products previously recognized on a gross basis were recognized on a net basis during the three months ended ~~January~~October 27, 2018, resulting in an estimated ~~2.0%~~0.2% unfavorable impact to sales. Positive end market fundamentals contributed to the current quarter sales growth.

Gross Profit. Consolidated gross profit margin rate for the three months ended ~~January~~October 27, 2018 decreased ~~220~~180 basis points from the prior year quarter to ~~21.4%~~21.0%. Gross profit margin rates decreased in both the Dental and Animal Health segments during the three months ended ~~January~~October 27, 2018. A greater percentage of sales came from our lower margin Animal Health segment during the three months ended October 27, 2018, resulting in a lower consolidated gross profit margin rate. Unfavorable sales mix, pricing pressure at the point of sale and ~~lower rebates~~inventory adjustments in both our Dental

and Animal Health segment ~~were the primary drivers of~~also contributed to the decline in the gross profit margin rate. In addition, lower net sales in our Corporate segment related to customer financing contracts reduced the gross profit margin rate.

Operating Expenses. Consolidated operating expenses for the three months ended October 27, 2018 were $253.9 million, a 4.0% increase from the prior year quarter of $244.0 million. We incurred higher operating expenses during the three months ended October 27, 2018 primarily as a result of higher professional services expenses. The consolidated operating expense ratio of 18.1% increased 50 basis points from the prior year quarter, which was also driven by this same factor.

Operating Income. For the three months ended October 27, 2018, operating income was $41.2 million, or 2.9% of net sales, as compared to $71.8 million, or 5.2% of net sales for the three months ended October 28, 2017. The decrease in operating income and operating income as a percent of sales was primarily due to a decrease in operating margins in the Dental segment and higher professional services expenses. In addition, a greater percentage of sales came from our lower margin Animal Health segment during the three months ended ~~January~~October 27, 2018, ~~resulting in~~which lowered operating income as a ~~lower consolidated gross profit margin rate.~~percent of sales.

~~Operating Expenses.~~ ~~Consolidated~~Dental segment operating ~~expenses~~income was $41.6 million for the three months ended ~~January~~October 27, 2018, ~~were $244.7~~a decrease of $23.6 million ~~a 13.6% decrease~~ from the prior year ~~quarter of $283.2 million. We incurred higher operating expenses during the three months ended January 28, 2017 primarily as a result of the intangible asset impairment charge in our Dental segment.~~quarter. The ~~consolidated operating expense ratio of 17.8% decreased 250 basis points from the prior year quarter.~~

~~The~~ decrease ~~in this ratio was driven by the impairment charge in the prior year quarter, partially offset by lower net sales in the current quarter.~~

~~Operating Income From Continuing Operations.~~ For the three months ended January 27, 2018, operating income from continuing operations was $50.0 million, or 3.6% of net sales, as compared to $46.6 million, or 3.3% of net sales for the three months ended January 28, 2017. The increase in operating income from continuing operations was primarily due to ~~the impairment charge in the prior year quarter, partially offset by~~ lower net sales and a lower gross profit margin rate in the current ~~quarter. The increase~~quarter, in addition to greater operating income from continuing operations as a percent of sales was driven by these same factors. In addition, a greater percentage of sales came from our lower margin Animal Health segment during the three months ended January 27, 2018, which lowered operating income from continuing operations as a percent of sales.

Dental segment operating income was $58.4 million for the three months ended January 27, 2018, an increase of $18.4 million from the prior year quarter. The increase was primarily due to the impairment charge in the prior year quarter, partially offset by lower net sales and a lower gross profit margin rate in the current quarter.expenses.

Animal Health segment operating income was ~~$18.0~~$22.0 million for the three months ended ~~January~~October 27, 2018, a decrease of ~~$5.7~~$1.2 million from the prior year quarter. The decrease was primarily due to ~~unfavorable sales mix and lower rebates.~~greater operating expenses incurred during the three months ended October 27, 2018.

Corporate segment operating loss was ~~$26.4~~$22.4 million for the three months ended ~~January~~October 27, 2018, as compared to a loss of ~~$17.2~~$16.7 million for the three months ended ~~January~~October 28, 2017. The change was driven primarily by ~~a decrease in the gain on sale~~higher professional services expenses, as well as lower net sales related to our customer financing ~~programs.~~contracts during the three months ended October 27, 2018.

Other Income (Expense). Net other expense for the three months ended ~~January~~October 27, 2018 was ~~$9.7~~$3.5 million, compared to ~~$10.4~~$10.3 million for the three months ended ~~January~~October 28, 2017. Net other expense was lower during the three months ended October 27, 2018 due to the recognition of a gain related to an investment, as well as lower interest expense.

Income Tax Expense ~~(Benefit)~~. The effective income tax rate for the three months ended ~~January~~October 27, 2018 was ~~(170.0)%~~24.0% compared to ~~23.2%~~34.5% for the three months ended ~~January~~October 28, 2017. The change in the tax ~~benefit for the three months ended January 27, 2018~~rate was primarily due to the impact of the Tax Act.

Net Income Attributable to Patterson Companies Inc. and Earnings Per ~~Share From Continuing Operations.~~Share. Net income ~~from continuing operations~~attributable to Patterson Companies Inc. for the three months ended ~~January~~October 27, 2018 was ~~$109.0~~$28.9 million, compared to ~~$27.8~~$40.2 million for the three months ended ~~January~~October 28, 2017. Earnings per diluted share ~~from continuing operations~~ were ~~$1.18~~$0.31 in the current quarter compared to ~~$0.29~~$0.43 in the prior year quarter. Weighted average diluted shares outstanding in the current quarter were ~~92.6~~93.3 million, compared to ~~95.4~~93.4 million in the prior year quarter. The current quarter and prior year quarter cash dividend was $0.26 per common ~~share compared to $0.24 in the prior year quarter.~~share.

~~Discontinued Operations~~

For the three months ended January 27, 2018 and January 28, 2017, net loss from discontinued operations was $0 and $3.2 million, respectively. The net loss incurred during the three months ended January 28, 2017 was due to a change in estimate of the tax impact of the sale of Patterson Medical, which was completed in August 2015.

~~NINE~~SIX MONTHS ENDED ~~JANUARY~~OCTOBER 27, 2018 COMPARED TO ~~NINE~~SIX MONTHS ENDED ~~JANUARY~~OCTOBER 28, 2017

~~Continuing Operations~~

The following table summarizes our results ~~from continuing operations~~ as a percent of net ~~sales from continuing operations:~~sales:


	Nine Months Ended				Six Months Ended
	January 27, 2018		January 28, 2017		October 27, 2018		October 28, 2017
Net sales	100.0	%	100.0	%	100.0	%	100.0	%
Cost of sales	77.6		76.7		78.9		77.1
Gross profit	22.4		23.3		21.1		22.9
Operating expenses	18.0		18.7		19.4		18.1
Operating income from continuing operations	4.4		4.6
Operating income					1.7		4.8
Other income (expense)	(0.7	)	(0.6	)	(0.5	)	(0.8	)
Income from continuing operations before taxes	3.7		4.0
Income tax expense (benefit)	(0.7	)	1.3
Net income from continuing operations	4.4	%	2.7	%
Income before taxes					1.2		4.0
Income tax expense					0.3		1.4
Net income					0.9		2.6
Net loss attributable to noncontrolling interests					—		—
Net income attributable to Patterson Companies, Inc.					0.9	%	2.6	%

Net Sales. Consolidated net sales for the ~~nine~~six months ended ~~January~~October 27, 2018 were ~~$4,065.1~~$2,741.1 million, a ~~2.0% decrease~~1.9% increase from ~~$4,148.1~~$2,689.9 million for the ~~nine~~six months ended ~~January~~October 28, 2017. Foreign exchange rate changes had a favorable impact of ~~0.2%~~0.1% on current period sales.

Dental segment sales for the ~~nine~~six months ended ~~January~~October 27, 2018 were ~~$1,650.3~~$1,048.6 million, a ~~7.4%~~2.2% decrease from ~~$1,782.9~~$1,072.4 million for the ~~nine~~six months ended ~~January~~October 28, 2017. Foreign exchange rate changes had ~~a favorable~~an insignificant impact ~~of 0.2%~~ on current period sales. Current period sales of consumables decreased ~~5.0%~~3.7%, sales of dental equipment and software increased 1.8% to $302.6 million, and sales of other dental services and products decreased 4.0% for the six months ended October 27, 2018. The decrease in sales of consumables was mainly due ~~primarily~~ to changes in our sales force and disruptions resulting from our ERP system initiatives. Sales of dental equipment and software decreased 14.0% to $504.4 million for the nine months ended January 27, 2018, due primarily to a decrease in sales of digital technology products, which was driven by our decision to broaden our technology equipment portfolio. In addition, we believe that our customers are delaying equipment purchases as they evaluate new digital product offerings. Sales of other dental services and products decreased 0.9% for the nine months ended January 27, 2018.

Animal Health segment sales for the ~~nine~~six months ended ~~January~~October 27, 2018 were ~~$2,394.6~~$1,680.6 million, a ~~2.7%~~5.1% increase from ~~$2,332.4~~$1,599.7 million for the ~~nine~~six months ended ~~January~~October 28, 2017. Foreign exchange rate changes had a favorable impact of ~~0.2%~~0.1% on current period sales. Sales of certain products previously recognized on a gross basis were recognized on a net basis during the ~~nine~~six months ended ~~January~~October 27, 2018, resulting in an estimated ~~2.3%~~0.3% unfavorable impact to sales. Positive end market fundamentals contributed to the current period sales growth.

Gross Profit. Consolidated gross profit margin rate for the ~~nine~~six months ended ~~January~~October 27, 2018 decreased 90180 basis points from the prior year period to ~~22.4%~~21.1%. Gross profit margin rates decreased in both the Dental and Animal Health segment. A greater percentage of sales came from our lower margin Animal Health segment during the six months ended October 27, 2018, resulting in a lower consolidated gross profit margin rate. Unfavorable sales mix, pricing pressure at the point of sale and ~~lower rebates~~inventory adjustments in both our Dental and Animal Health segment ~~were the primary drivers of~~also contributed to the decline in the gross profit margin rate. In addition, lower net sales in our Corporate segment related to customer financing contracts reduced the gross profit margin rate.

Operating Expenses. Consolidated operating expenses for the six months ended October 27, 2018 were $533.0 million, a 9.6% increase from the prior year period of $486.2 million. We incurred higher operating expenses during the six months ended October 27, 2018 primarily as a result of the Legal Reserve, higher professional services expenses and higher personnel costs. The consolidated operating expense ratio of 19.4% increased 130 basis points from the prior year period, which was also driven by these same factors.

Operating Income. For the six months ended October 27, 2018, operating income was $45.7 million, or 1.7% of net sales, as compared to $128.6 million, or 4.8% of net sales for the six months ended October 28, 2017. The decrease in operating income and operating income as a percent of sales was primarily due to a decrease in operating margins in our Dental segment, the impact of the Legal Reserve and higher professional services expenses. In addition, a greater percentage of sales came from our lower margin Animal Health segment during the ~~nine~~six months ended ~~January~~October 27, 2018, ~~resulting in~~which lowered operating income as a ~~lower consolidated gross profit margin rate.~~percent of sales.

~~Operating Expenses.~~ ~~Consolidated~~Dental segment operating ~~expenses~~income was $77.5 million for the ~~nine~~six months ended ~~January~~October 27, 2018, ~~were $730.9~~a decrease of $47.3 million a 5.6% decrease from the prior year period of $774.1 million. We incurred higher operating expenses during the nine months ended January 28, 2017 primarily as a result of the intangible asset impairment charge in our Dental segment. The decrease in consolidated operating expenses for the nine months ended January 27, 2018 was also driven by cost containment efforts, partially offset by increased expenses related to our ERP system initiatives. The consolidated operating expense ratio of 18.0% decreased 70 basis points from the prior year period. The decrease ~~in this ratio~~ was ~~driven by these same factors.~~

~~Operating Income From Continuing Operations.~~ ~~For the nine months ended January 27, 2018, operating income from continuing operations was $178.6 million, or 4.4% of net sales, as compared~~primarily due to ~~$191.8 million, or 4.6% of net sales for the nine months ended January 28, 2017. The decrease in operating income from continuing operations was driven by~~ lower net sales and ~~increased expenses related to our ERP system initiatives, partially offset by the intangible asset impairment charge recorded~~a lower gross profit margin rate in the ~~nine months ended January 28, 2017 and cost containment efforts. The decrease~~current period, in addition to greater operating income from continuing operations as a percent of sales was driven by these same factors. In addition, a greater percentage of sales came from our lower margin Animal Health segment during the nine months ended January 27, 2018, which reduced operating income from continuing operations as a percent of sales.expenses.

~~Dental~~Animal Health segment operating income was ~~$183.2~~$41.1 million for the ~~nine~~six months ended ~~January~~October 27, 2018, an increase of ~~$5.8~~$1.2 million from the prior year period. The increase was primarily due to ~~the impairment charge in the prior year period and cost containment efforts during the nine months ended January 27, 2018,~~higher net sales, partially offset by ~~lower net sales and increased expenses related to our ERP system initiatives.~~

~~Animal Health segment~~greater operating income was $57.9 million for the nine months ended January 27, 2018, a decrease of $2.5 million from the prior year period. The decrease was primarily due to increased expenses related to our ERP system initiatives and lower rebates.expenses.

Corporate segment operating loss was ~~$62.5~~$72.8 million for the ~~nine~~six months ended ~~January~~October 27, 2018, as compared to a loss of ~~$46.0~~$36.0 million for the ~~nine~~six months ended ~~January~~October 28, 2017. The change was driven primarily by ~~a decrease in~~ the ~~gain on sale related to our customer financing programs,~~Legal Reserve established during the first quarter of fiscal 2019, as well as higher ~~expenses due to a separation agreement with our former chief executive officer.~~professional services expenses.

Other Income (Expense)~~, Net.~~. Net other expense was ~~$29.7~~$13.5 million for the ~~nine~~six months ended ~~January~~October 27, 2018, compared to ~~$26.7~~$20.0 million for the ~~nine~~six months ended ~~January~~October 28, 2017. ~~The increase~~Net other expense was ~~mainly~~lower during the six months ended October 27, 2018 due to ~~higher~~the recognition of a gain related to an investment, as well as lower interest ~~expense in the current period.~~expense.

Income Tax Expense ~~(Benefit)~~. The effective income tax rate for the ~~nine~~six months ended ~~January~~October 27, 2018 was ~~(20.9)%~~25.1% compared to ~~31.9%~~34.5% for the ~~nine~~six months ended ~~January~~October 28, 2017. The change in the tax ~~benefit for the nine months ended January 27, 2018~~rate was primarily due to the impact of the Tax ~~Act.~~Act and lower excess tax benefits on employee share-based compensation.

Net Income Attributable to Patterson Companies Inc. and Earnings Per ~~Share From Continuing Operations.~~Share. Net income ~~from continuing operations~~attributable to Patterson Companies Inc. for the ~~nine~~six months ended ~~January~~October 27, 2018 was ~~$180.0~~$24.1 million, compared to ~~$112.4~~$71.1 million for the ~~nine~~six months ended ~~January~~October 28, 2017. Earnings per diluted share ~~from continuing operations~~ were ~~$1.93~~$0.26 in the current period compared to ~~$1.17~~$0.76 in the prior year period. Weighted average diluted shares outstanding in the current period were ~~93.3~~93.1 million compared to ~~95.9~~93.7 million in the prior year period. The current period and prior year period cash dividend was ~~$0.78~~$0.52 per common ~~share compared to $0.72 in the prior year period.~~share.

~~Discontinued Operations~~

For the nine months ended January 27, 2018 and January 28, 2017, net loss from discontinued operations was $0 and $3.2 million, respectively. The net loss incurred during the nine months ended January 28, 2017 was due to a change in estimate of the tax impact of the sale of Patterson Medical, which was completed in August 2015.

LIQUIDITY AND CAPITAL RESOURCES

For the ~~nine~~six months ended ~~January~~October 27, 2018, net cash provided by operating activities was ~~$40.0~~$200.2 million, compared to net cash ~~used in~~provided by operating activities of ~~$12.6~~$77.1 million for the ~~nine~~six months ended ~~January~~October 28, 2017. The net cash provided by operating activities during the ~~nine~~six months ended ~~January~~October 27, 2018 was primarily driven by ~~net income~~a reduction in working capital and the impact of ~~$180.0 million, partially offset by growth in consumable and equipment inventory. The improvement in operating cash flows for~~ the ~~nine~~Receivables Securitization Program.

For the six months ended ~~January 27, 2018 was primarily due to increased collections of accounts receivable.~~

~~For the nine months ended January~~October 27, 2018, net cash provided by investing activities was ~~$19.4~~$146.3 million, compared to net cash ~~used in~~provided by investing activities of ~~$1.6~~$19.8 million for the ~~nine~~six months ended ~~January~~October 28, 2017. The change in net cash flows was primarily driven by the sale of a property during the nine months ended January 27, 2018 for $11.6 million, as well as lower additions to property and equipment during the nine months ended January 27, 2018, which was largely due to lower expenditures on our ERP system. Net cash flows for the ~~nine~~six months ended ~~January~~October 27, 2018 were positive primarily due to the collection of ~~$37.1~~$165.6 million of deferred purchase price receivables. We expect to use a total of approximately ~~$40~~$70 million for capital expenditures in fiscal ~~2018.~~2019.

Net cash used in financing activities for the ~~nine~~six months ended ~~January~~October 27, 2018 was ~~$42.0~~$242.7 million. Uses of cash consisted primarily of ~~$87.5~~$180.3 million for retirement of long-term debt and $50.0 million for dividend payments. For the six months ended October 28, 2017, net cash used in financing activities was $92.0 million. Uses of cash consisted primarily of $71.3 million for share repurchases and ~~$74.6~~$50.0 million for dividend payments. Cash proceeds included ~~$120.0~~$33.0 million attributed to draws on our revolving line of credit. For the nine months ended January 28, 2017, net cash provided by financing activities was $4.1 million. Cash proceeds included $178.0 million attributed to draws on our revolving line of credit. Uses of cash consisted primarily of $84.7 million for share repurchases and $70.9 million for dividend payments.

During fiscal 2016, we entered into a credit agreement ("Credit Agreement"), under which the lenders provided us with senior unsecured lending facilities of up to $1.5 billion, consisting of a $1.0 billion unsecured term loan and a $500 million unsecured revolving line of credit. In fiscal 2017, we entered into an ~~amendment of the Credit Agreement~~amended credit agreement (“Amended Credit Agreement”), consisting of a $295.1 million term loan and a $750 million revolving line of credit. Interest on borrowings is variable and is determined as a base rate plus a spread. This spread, as well as a commitment fee on the unused portion of the facility, is based on our leverage ratio, as defined in the Amended Credit Agreement. The term loan and revolving credit facilities will mature no later than January 2022.

As of ~~January~~October 27, 2018, ~~$284.0~~$96.3 million of the Amended Credit Agreement unsecured term loan was outstanding at an interest rate of ~~2.80%~~3.79%, and ~~$179.0~~no amount was outstanding under the Amended Credit Agreement revolving line of credit. At April 28, 2018, $276.6 million was outstanding under the Amended Credit Agreement unsecured term loan at an interest rate of 3.40%, and $16.0 million was outstanding under the Amended Credit Agreement revolving line of credit at an interest rate of 2.70%. At April 29, 2017, $291.4 million was outstanding under the Amended Credit Agreement unsecured term loan at an interest rate of 2.24%, and $59.0 million was outstanding under the Amended Credit Agreement revolving line of credit at an interest rate of 2.19%2.95%.

We expect funds generated from operations, existing cash balances and credit availability under existing debt facilities will be sufficient to meet our working capital needs and to finance strategic initiatives over the remainder of fiscal ~~2018.~~2019.

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

See Note 1 to the Condensed Consolidated Financial Statements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There have been no material changes in our exposure to market risk from that disclosed in Item 7A in our ~~2017~~2018 Annual Report on Form 10-K filed June ~~28, 2017.~~27, 2018.

ITEM 4. CONTROLS AND PROCEDURES

Under the supervision and with the participation of our management, including our President and Chief Executive Officer ("CEO") and our Chief Financial Officer ("CFO"), management evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) as of ~~January~~October 27, 2018. Based upon their evaluation of these disclosure controls and procedures, the CEO and CFO concluded that the disclosure controls and procedures were effective as of ~~January~~October 27, 2018.

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended ~~January~~October 27, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Beginning in January 2016, purported antitrust class action complaints were filed against defendants Henry Schein, Inc., Benco Dental Supply Company and Patterson Companies, Inc. Although there were factual and legal variations among these complaints, each alleged that defendants conspired to foreclose and exclude competitors by boycotting manufacturers, state dental associations, and others that deal with defendants’ competitors. On February 9, 2016, the U.S. District Court for the Eastern District of New York ordered all of these actions, and all other actions filed thereafter asserting substantially similar claims against defendants, consolidated for pre-trial purposes. On February 26, 2016, a consolidated class action complaint was filed by Arnell Prato, D.D.S., P.L.L.C., d/b/a Down to Earth Dental, Evolution Dental Sciences, LLC, Howard M. May, DDS, P.C., Casey Nelson, D.D.S., Jim Peck, D.D.S., Bernard W. Kurek, D.M.D., Larchmont Dental Associates, P.C., and Keith Schwartz, D.M.D., P.A. (collectively, “putative class representatives”) in the U.S. District Court for the Eastern District of New York, entitled In re Dental Supplies Antitrust Litigation, Civil Action No. 1:16-CV-00696-BMC-GRB. Subject to certain exclusions, the putative class representatives seek to represent all ~~persons~~private dental practices and laboratories who purchased dental supplies or equipment in the U.S. directly from any of the defendants, ~~since~~during the period beginning August 31, ~~2008.~~2008 until March 31, 2016. In the consolidated class action complaint, putative class representatives allege a nationwide agreement among Henry Schein, Benco, Patterson and non-party Burkhart Dental Supply Company, Inc. not to compete on price. The consolidated class action complaint asserts a single count under Section 1 of the Sherman Act, and seeks equitable relief, compensatory and treble damages, jointly and severally, interest, and reasonable costs and expenses, including attorneys’ fees and expert fees. ~~While~~On September 28, 2018, the ~~outcome~~parties executed a settlement agreement that proposes a full and final settlement of ~~litigation is inherently uncertain,~~the lawsuit on a class-wide basis, subject to court approval. Related to this settlement, we ~~believe the consolidated class action complaint is without merit, and we are vigorously defending ourselves~~recorded a charge of $28.3 million in ~~this litigation.~~our first quarter 2019 results in our Corporate segment.

On August 31, 2012, Archer and White Sales, Inc. (“Archer”) filed a complaint against Henry Schein, Inc. as well as Danaher Corporation and its subsidiaries Instrumentarium Dental, Inc., Dental Equipment, LLC, Kavo Dental Technologies, LLC and Dental Imaging Technologies Corporation (collectively, the “Danaher Defendants”) in the United States District Court for the Eastern District of Texas, Civil Action No. 2:12-CV-00572-JRG, styled as an antitrust action under Section 1 of the Sherman Act, and the Texas Free Enterprise Antitrust Act. Archer alleges a conspiracy between Henry Schein, an unnamed company and the Danaher Defendants to terminate or limit Archer’s distribution rights. On August 1, 2017, Archer filed an amended complaint, adding Patterson Companies, Inc. and Benco Dental Supply Company as defendants, and alleging that Henry Schein, Patterson, Benco and non-defendant Burkhart Dental Supply Company, Inc. conspired to pressure and agreed to enlist their common suppliers, including the Danaher Defendants, to join a price-fixing conspiracy and boycott by reducing the distribution territory of, and eventually terminating, Archer. Archer seeks injunctive relief, and damages in an amount to be proved at trial, to be trebled with interest and costs, including attorneys’ fees, jointly and severally. On ~~March 2,~~June 25, 2018, ~~the case was stayed by~~ the United States Supreme Court ~~pending its decision as to whether~~granted certiorari to review an arbitration issue raised by the Danaher ~~Defendants.~~Defendants, thereby continuing the case stay implemented in March 2018. On October 29, 2018, the United States Supreme Court heard oral argument. The United States Supreme Court’s decision is pending. We are vigorously defending ourselves in this litigation. We do not anticipate that this matter will have a material adverse effect on our financial statements.

SourceOne for the marketing, distribution and sale of dental supplies and equipment in the United States, and that defendants unlawfully agreed with one another to boycott dentists, manufacturers and state dental associations that deal with, or considered dealing with, plaintiff and SourceOne. Plaintiff claims that this alleged conduct constitutes unreasonable restraint of trade in violation of Section 1 of the Sherman Act, New York’s Donnelly Act and the New Jersey Antitrust Act, and also makes pendant state law claims for tortious interference with prospective business relations, civil conspiracy and aiding and abetting. Plaintiff seeks injunctive relief, compensatory, treble and punitive damages, jointly and severally, and reasonable costs and expenses, including attorneys’ fees and expert fees. On December 21, 2017, the District Court granted defendants motion to dismiss the complaint with prejudice. Plaintiff has appealed to the ~~Fifth Circuit~~District Court’s order. The U.S. Court of ~~Appeals.~~Appeals for the Second Circuit heard oral argument on the appeal on September 13, 2018. The court’s decision is pending. We are vigorously defending ourselves in this litigation. We do not anticipate that this matter will have a material adverse effect on our financial statements.

On February 12, 2018, the Federal Trade Commission (“FTC”) issued an administrative complaint entitled In the Matter of Benco Dental Supply Co., Henry Schein, Inc., and Patterson Companies, Inc. Docket No. 9379. The administrative complaint alleges “reason to believe” that Patterson and the other respondents violated Section 5 of the FTC Act, 15 U.S.C. § 45 by conspiring to refuse to offer discounted prices or otherwise negotiate with buying groups seeking to obtain supply agreements on behalf of groups of solo practitioners or small group dental practices. The administrative complaint seeks injunctive relief against Patterson, including an order to cease and desist from the conduct alleged in the complaint and a prohibition from conspiring or agreeing with any competitor or any person to refuse to provide discounts to or compete for the business of any customer. No money damages are sought. We ~~intend to~~are vigorously ~~defend~~defending ourselves against the administrative complaint. The ~~administrative complaint provides notice of an October 16, 2018~~ hearing in front of an Administrative Law Judge of the FTC in Washington, D.C. began on October 16, 2018 and is ongoing. We do not anticipate this matter will have a material adverse effect on our financial statements.

conducting an internal investigation and are cooperating with the U.S. Attorney’s Office. At this time, we are unable to make an estimate of the amount of loss, if any, or range of possible loss that we could incur as a result of the foregoing matter.

On August 28, 2018, Kirsten Johnsen filed a stockholder derivative complaint against Patterson Companies, Inc., as a nominal defendant, and the following former and current officers and directors of Patterson: Scott Anderson, Ann Gugino, James Wiltz, John Buck, Jody Feragen, Ellen Rudnick, Les Vinney, Neil Schrimsher, Sarena Lin, Harold Slavkin, Alex Blanco and Mark Walchirk as individual defendants in Hennepin County District Court in a case captioned Kirsten Johnsen v. Scott P. Anderson et al., Case No. 27-CV-18-14315. Derivatively on behalf of Patterson, plaintiff alleges that Patterson “suppressed price competition and maintained supracompetitive prices for dental supplies and equipment by entering into agreements with Henry Schein and Benco to: (i) fix margins for dental supplies and equipment; and (ii) block the entry and expansion of lower-margin, lower-priced, rival dental distributors through threatened and actual group boycotts.” Plaintiff further alleges that the individual defendants failed to disclose Patterson’s alleged “price-fixing scheme” to the public and purportedly “caused Patterson to repurchase over $412.8 million worth of its own stock at artificially inflated prices.” In the derivative complaint, plaintiff asserts three counts against the individual defendants for: (i) breach of fiduciary duty; (ii) waste of corporate assets; and (iii) unjust enrichment. Plaintiff seeks compensatory damages, equitable and injunctive relief as permitted by law, costs, disbursements and reasonable attorneys’ fees, accountants’ fees and experts’ fees, costs and expenses, and an order awarding restitution from the individual defendants and directing Patterson “to take all necessary actions to reform and improve its corporate governance and internal procedures.” While the outcome of litigation is inherently uncertain, we believe that the derivative complaint is without merit, and we intend to vigorously defend ourselves in this litigation. We do not anticipate that this matter will have a material adverse effect on our financial statements.

On October 1, 2018, Sally Pemberton filed a stockholder derivative complaint against Patterson Companies, Inc., as a nominal defendant, and the following former and current officers and directors of Patterson: Scott Anderson, Ann Gugino, Mark Walchirk, John Buck, Alex Blanco, Jody Feragen, Sarena Lin, Ellen Rudnick, Neil Schrimsher, Les Vinney, James Wiltz, Paul Guggenheim, David Misiak and Tim Rogan as individual defendants in the United States District Court for the District of Minnesota in a case captioned Sally Pemberton v. Scott P. Anderson, et al., Case No. 18-CV-2818. Derivatively on behalf of Patterson, plaintiff alleges that Patterson, with Benco and Henry Schein, “engage[d] in a conspiracy in restraint of trade, whereby the companies agreed to refuse to offer discounted prices or otherwise negotiate with GPOs, agreed to fix margins on dental supplies and equipment, agreed not to poach one another’s customers or sales representatives, and agreed to block the entry and expansion of rival distributors. Plaintiff further alleges that the individual defendants failed to disclose Patterson’s alleged “antitrust misconduct” to the public and purportedly caused Patterson to repurchase $412.8 million of its own stock at prices that were artificially inflated. In the derivative complaint, plaintiff asserts six counts against the individual defendants for: (i) breach of fiduciary duty; (ii) waste of corporate assets; (iii) unjust enrichment; (iv) violations of Section 14(a) of the Exchange Act; (v) violations of Section 10(b) and Rule 10b-5 of the Exchange Act and (vi) violations of Section 20(a) of the Exchange Act. Plaintiff seeks compensatory damages with pre-judgment and post-judgment interest, costs, disbursements and reasonable attorneys’ fees, experts’ fees, costs and expenses, and an order awarding restitution from the individual defendants and directing Patterson “to take all necessary actions to reform and improve its corporate governance and internal procedures.” While the outcome of litigation is inherently uncertain, we believe that the derivative complaint is without merit, and we intend to vigorously defend ourselves in this litigation. We do not anticipate that this matter will have a material adverse effect on our financial statements.

of the claims pending against us may result in significant monetary damages or injunctive relief against us that could adversely affect our ability to conduct our business. There also exists the possibility of a material adverse effect on our financial statements for the period in which the effect of an unfavorable final outcome becomes probable and reasonably estimable.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Purchases of Equity Securities by the Issuer

On March ~~19, 2013, our~~13, 2018, the Board of Directors ~~approved~~authorized a new $500 million share repurchase program through March 13, 2021. The new repurchase program replaced the remaining authorization from our previous plan ~~that replaced a previously existing share repurchase plan. Under the March 19, 2013 plan,~~to purchase up to 25 million shares, ~~may be purchased in open market transactions through~~which was scheduled to expire on March 19, 2018.

~~The following table presents activity~~No shares were repurchased under the stock repurchase plan during the ~~third~~second quarter of fiscal ~~2018:~~2019.

Total
Number of
Shares
Purchased Average
Price Paid
per Share Total Number of
Shares Purchased
as Part of Publicly
Announced Plans
or Programs Maximum
Number of Shares
That May Yet Be
Purchased Under
the Plan
October 29, 2017 to November 25, 2017 —
$ —
—
11,863,934
November 26, 2017 to December 23, 2017 123,436
36.43
123,436
11,740,498
December 24, 2017 to January 27, 2018 245,071
36.74
245,071
11,495,427
368,507
$ 36.63
368,507
11,495,427

During fiscal 2016, we entered into a credit agreement ("Credit Agreement"), under which the lenders provided us with senior unsecured lending facilities of up to $1.5 billion, consisting of a $1.0 billion unsecured term loan and a $500 million unsecured revolving line of credit. The Credit Agreement was due to expire in fiscal 2021. In fiscal 2017, we entered into an ~~amendment of the Credit Agreement~~amended credit agreement (“Amended Credit Agreement”), consisting of a $295.1 million term loan and a $750 million revolving line of credit. The Amended Credit Agreement permits us to declare and pay

dividends, and repurchase shares, provided that no default or unmatured default exists and that we are in compliance with applicable financial covenants.

ITEM 6. EXHIBITS



Exhibit No.		Exhibit Description

10.1		Amended and Restated Contract Purchase Agreement dated as of August 12, 2011, among PDC Funding Company II, LLC, as seller, Patterson Companies, Inc., as servicer, the purchasers party thereto, and Fifth Third Bank, as agent, conformed through Tenth Amendment, dated August 3, 2018 (incorporated by reference to our Quarterly Report on Form 10-Q, filed September 5, 2018 (File No. 000-20572)).).

10.2		Third Amended and Restated Receivables Purchase Agreement dated as of December 3, 2010, among PDC Funding Company, LLC, as seller, Patterson Companies, Inc., as servicer, the conduits party thereto, the financial institutions party thereto, the purchaser agents party thereto, and MUFG Bank, Ltd. (f.k.a. The Bank of Tokyo-Mitsubishi UFJ, Ltd.), as agent, conformed through Thirteenth Amendment dated August 10, 2018 (incorporated by reference to our Quarterly Report on Form 10-Q, filed September 5, 2018 (File No. 000-20572)).).

10.3		Patterson Companies, Inc. Amended and Restated Capital Accumulation Plan (filed herewith).

10.4		Patterson Companies, Inc. Amended and Restated 2015 Omnibus Incentive Plan (incorporated by reference to Annex A to our Definitive Schedule 14A (Proxy Statement), filed August 6, 2018 (File No. 000-20572)).

31.1		Certification of the Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101		Financials in XBRL format.

All other items under Part II have been omitted because they are inapplicable or the answers are negative, or were previously reported in the ~~2017~~2018 Annual Report on Form 10-K filed June ~~28, 2017.~~

27, 2018.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



		PATTERSON COMPANIES, INC.
		(Registrant)

Dated: ~~March 7,~~December 6, 2018	By:		/s/ Donald J. Zurbay

	~~By:~~	~~/s/ Dennis W. Goedken~~Donald J. Zurbay
		~~Dennis W. Goedken~~
		~~Interim~~ Chief Financial Officer and Treasurer
		(Principal Financial Officer and Principal Accounting Officer)

2431



	Total Number of Shares Purchased	Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Maximum Number of Shares That May Yet Be Purchased Under the Plan
October 29, 2017 to November 25, 2017	—	$	—	—	11,863,934
November 26, 2017 to December 23, 2017	123,436	36.43		123,436	11,740,498
December 24, 2017 to January 27, 2018	245,071	36.74		245,071	11,495,427
	368,507	$	36.63	368,507	11,495,427